

**YEDİTEPE UNIVERSITY  
FACULTY OF MEDICINE  
PHASE III  
ACADEMIC PROGRAM BOOK  
2024- 2025**

**Student's**

**Name** : .....

**Number** : .....



**YEDİTEPE UNIVERSITY**  
**FACULTY OF MEDICINE**  
**PHASE III**

<b>CONTENT</b>	<b>Page</b>
<b>COORDINATION COMMITTEE.....</b>	<b>4</b>
<b>ACADEMIC CALENDAR 2024 - 2025.....</b>	<b>5</b>
<b>INSTRUCTIONAL DESIGN of PRECLINICAL YEARS .....</b>	<b>7</b>
<b>AIM OF MEDICAL EDUCATION PROGRAM .....</b>	<b>8</b>
<b>PROGRAM OUTCOMES OF MEDICAL EDUCATION .....</b>	<b>9</b>
<b>2024-2025 CURRICULUM OF PHASE III .....</b>	<b>12</b>
<b>DESCRIPTION and CONTENT of PHASE III .....</b>	<b>13</b>
<b>AIM and LEARNING OBJECTIVES of PHASE III.....</b>	<b>14</b>
<b>AIM and LEARNING OBJECTIVES of CLINICAL SCIENCES (MED 302) .....</b>	<b>16</b>
<b>DESCRIPTION of INTRODUCTION to CLINICAL PRACTICE I, II and III (ICP-I,-II,-III) (MED 102, 202, 303).....</b>	<b>18</b>
<b>AIM and LEARNING OBJECTIVES of INTRODUCTION to CLINICAL PRACTICE III (ICP-III) (MED 303).....</b>	<b>20</b>
<b>MED 303 ICP III COURSE 2024-2025 ACADEMIC PROGRAM .....</b>	<b>21</b>
<b>AIM and LEARNING OBJECTIVES of SCIENTIFIC RESEARCH and PROJECT COURSE- III.....</b>	<b>27</b>
<b>ASSESSMENT PROCEDURE.....</b>	<b>29</b>
<b>RULES FOR COURSE ATTENDANCE OF THE STUDENTS.....</b>	<b>32</b>
<b>EXAM RULES .....</b>	<b>33</b>
<b>PROGRESS TEST .....</b>	<b>34</b>
<b>AIM OF FREE ELECTIVE COURSES .....</b>	<b>35</b>
<b>SPECIFIC SESSIONS / PANELS.....</b>	<b>36</b>
<b>COMMITTEE EVALUATION SESSION .....</b>	<b>37</b>
<b>PROGRAM IMPROVEMENT SESSION.....</b>	<b>38</b>
<b>MULTIDISCIPLINARY CASE DISCUSSION PANEL .....</b>	<b>39</b>
<b>INDEPENDENT LEARNING .....</b>	<b>40</b>
<b>COURSE LOCATIONS .....</b>	<b>41</b>
<b>RECOMMENDED TEXTBOOKS .....</b>	<b>42</b>
<b>COMMITTEE I - INFECTIOUS DISEASES &amp; HEMATOPOIETIC SYSTEM .....</b>	<b>44</b>
<b>COMMITTEE II - CARDIOVASCULAR &amp; RESPIRATORY SYSTEMS .....</b>	<b>56</b>
<b>COMMITTEE III - GASTROINTESTINAL SYSTEM .....</b>	<b>67</b>
<b>COMMITTEE IV - ENDOCRINE, REPRODUCTIVE &amp; URINARY SYSTEMS .....</b>	<b>76</b>
<b>COMMITTEE V - NERVOUS SYSTEM AND PSYCHIATRY .....</b>	<b>88</b>
<b>COMMITTEE VI - MUSCULOSKELETAL SYSTEM .....</b>	<b>99</b>
<b>STUDENT COUNSELING.....</b>	<b>109</b>
<b>CONTACT .....</b>	<b>110</b>

**COORDINATION COMMITTEE**  
**(TEACHING YEAR 2024 – 2025)**

**PHASE-III COORDINATION COMMITTEE**

Deniz KIRAÇ, PhD, Prof. (Coordinator)  
Yeşim ÖZARDA, MD, Prof. (Co-coordinator)  
Figen ATALAY, MD, Prof. (Co-coordinator)  
Emine Nur ÖZDAMAR, MD, Assist. Prof. (Co-coordinator)  
Erdem SÖZTUTAR, MD, Assist. Prof. (Co-coordinator)  
Cenk ANDAÇ, PhD, Assist. Prof. (Co-coordinator)  
Başak ARU, PhD, Assist. Prof. (Co-coordinator)  
Büşra NİZAM, MD, Assist. Prof. (Co-coordinator)  
Didem SEVEN, PhD, Instructor (Co-coordinator)

**ICP-III COORDINATION COMMITTEE**

Güldal İZBIRAK, MD, Prof. (Coordinator)  
Duygu ALTIPARMAK, MD, Specialist, Instructor (Co-Coordinator)

**ELECTIVE COURSES COORDINATION COMMITTEE**

Seda GÜLEÇ YILMAZ, PhD, Assoc. Prof. (Coordinator)  
Ahmet SAÇ, MD, Instructor (Co-coordinator)

## ACADEMIC CALENDAR 2024 - 2025

### INTRODUCTION to CLINICAL SCIENCES (MED 302)

#### COMMITTEE I

##### INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEMS (8 Weeks)

Beginning of Committee	September 9, 2024	Monday
End of Committee	November 1, 2024	Friday
Committee Exam	November 1, 2024	Friday
National Holiday	October 28 <sup>1/2</sup> , 2024 October 29, 2024	Monday, Tuesday

#### COMMITTEE II

##### CARDIOLOGY and RESPIRATORY SYSTEMS (7 Weeks)

Beginning of Committee	November 4, 2024	Monday
End of Committee	December 20, 2024	Friday
Committee Exam	December 20, 2024	Friday

Commemoration of Atatürk	November 10, 2024	Sunday
--------------------------	-------------------	--------

#### COMMITTEE III

##### GASTROINTESTINAL SYSTEM (4 Weeks)

Beginning of Committee	December 23, 2024	Monday
End of Committee	January 16, 2025	Thursday
Committee Exam	January 16, 2025	Thursday
First Progress Test	December 28, 2024	Saturday
New Year	January 01, 2025	Wednesday

MIDTERM BREAK	Jan 20 – Jan 31, 2025
---------------	-----------------------

#### COMMITTEE IV

##### ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS (7 Weeks)

Beginning of Committee	February 3, 2025	Monday
End of Committee	March 21, 2025	Friday
Committee Exam	March 21, 2025	Friday

Physicians' Day	March 14, 2025	Friday
-----------------	----------------	--------

#### COMMITTEE V

##### NERVOUS SYSTEM and PSYCHIATRY (7 Weeks)

Beginning of Committee	March 24, 2025	Monday
End of Committee	May 9, 2025	Friday
Committee Exam	May 9, 2025	Friday

Religious Holiday	Mar 29 <sup>1/2</sup> – Apr 1, 2025	Saturday - Tuesday
National Holiday	April 23, 2025	Wednesday
Labor's Day	May 01, 2025	Thursday
Second Progress Test	May 10, 2025	Saturday

**COMMITTEE VI  
MUSCULOSKELETAL SYSTEM (6 Weeks)**

Beginning of Committee	May 12, 2025	Monday
End of Committee	June 19, 2025	Thursday
Committee Exam	June 19, 2025	Thursday

Religious Holiday	Jun 5 <sup>1/2</sup> – Jun 9, 2025	Thursday - Monday
National Holiday	May 19, 2025	Monday

**INTRODUCTION to CLINICAL SCIENCES (MED 302):**

Make-up Exam	June 24-26, 2025	Tuesday-Thursday
Final Exam	July 8, 2025	Tuesday
Incomplete Exam	July 25, 2025	Friday

**INTRODUCTION to CLINICAL PRACTICE – III (MED 303):**

Beginning of ICP - III	Sep 30, 2025	Monday
End of ICP - III	May 23, 2025	Friday
Midterm Exam	April 28, 2025	Monday
Make-up Exam	May 23, 2025	Friday
Final Exam	June 23-24, 2025	Monday-Tuesday
Incomplete Exam	July 3, 2025	Thursday

**FREE ELECTIVE COURSES:**

Introduction to Elective Courses	Jan 10, 2025	Friday
Beginning of Elective Courses	Feb 14, 2025	Friday
End of Elective Courses	May 23, 2025	Friday
Midterm Exam	April 11, 2025	Friday
Make-up Exam	May 26-30, 2025	Monday-Friday
Final Exam	June 10-18, 2025	Tuesday-Wednesday
Incomplete Exam	July 4-11, 2025	Friday-Friday

**COORDINATION COMMITTEE MEETINGS**

1 <sup>st</sup> Coordination Committee Meeting:	October 17, 2024	Thursday
2 <sup>nd</sup> Coordination Committee Meeting: (with student participation)	January 14, 2025	Tuesday
3 <sup>rd</sup> Coordination Committee Meeting: (with student participation)	May 27, 2025	Tuesday
4 <sup>th</sup> Coordination Committee Meeting:	July 17, 2025	Thursday

## **INSTRUCTIONAL DESIGN of PRECLINICAL YEARS**

In Phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of the human body such as macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of the human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in the human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as "Introduction to Clinical Practice -I, -II and -III" courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of each phase include learning objectives of core committees. The learning objectives of committees include learning objectives of core topics' components for the committee.

# YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

## AIM OF MEDICAL EDUCATION PROGRAM

\*“Consensus Commission Report” based on draft compiled at “*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*”

\*\*© 2011, Yeditepe University Faculty of Medicine

### AIM

The aim of medical education program *is to graduate physicians* who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know, apply** and **care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications



**YEDİTEPE UNIVERSITY**  
**FACULTY OF MEDICINE**  
**PROGRAM OUTCOMES OF MEDICAL EDUCATION**

YUTF - Undergraduate Medical Education Program was designed to provide our graduates with the competencies that are specified in the National Competencies List of medical graduates (UYYB).

UYYB is a national document that indicates the expected/required competencies of the students who are at the stage of graduating from Medical Schools in Turkey.

You can find UYYB from the

link: [https://www.yok.gov.tr/Documents/Kurumsal/egitim\\_ogretim\\_dairesi/Ulusal-cekirdek-egitimi-programlari/mezuniyet-oncesi-tip-egitimi-cekirdek-egitimi-programi.pdf](https://www.yok.gov.tr/Documents/Kurumsal/egitim_ogretim_dairesi/Ulusal-cekirdek-egitimi-programlari/mezuniyet-oncesi-tip-egitimi-cekirdek-egitimi-programi.pdf)

<b>COMPETENCY AREA-1 / Professional Practices</b>
<b>COMPETENCY 1.1. Health Service Provider</b>
<b>Competence 1.1.1.</b> Integrates knowledge, skills, and attitudes acquired from basic and clinical medical sciences, behavioral sciences, and social sciences to provide health services.
<b>Competence 1.1.2.</b> Demonstrates a biopsychosocial approach that considers the individual's sociodemographic and sociocultural background without discrimination based on language, religion, race, or gender in patient management.
<b>Competence 1.1.3.</b> Prioritizes the protection and improvement of individuals' and community's health in the delivery of healthcare services.
<b>Competence 1.1.4.</b> Performs the necessary actions in the direction of maintaining and improving the state of health as considering the individual, social, social and environmental factors affecting health.
<b>Competence 1.1.5.</b> Provides health education to healthy/ill individuals and their families, as well as to other healthcare professionals, by recognizing the characteristics, needs, and expectations of the target audience.
<b>Competence 1.1.6.</b> Demonstrates a safe, rational, and effective approach in the processes of protection, diagnosis, treatment, follow-up, and rehabilitation in health service delivery.
<b>Competence 1.1.7.</b> Performs interventional and/or non-interventional procedures safely and effectively for the patient in the processes of diagnosis, treatment, follow-up, and rehabilitation.
<b>Competence 1.1.8.</b> Provides healthcare services considering patient and employee health and safety.
<b>Competence 1.1.9.</b> Considers changes related to the physical and socio-economic environment at both regional and global scales that affect health, as well as changes in the individual characteristics and behaviors of those who seek healthcare services.
<b>COMPETENCY AREA-2 / Professional Values and Approaches</b>
<b>COMPETENCY 2.1. Adopting Professional Ethics and Principles</b>
<b>Competence 2.1.1.</b> Considers good medical practices while performing the profession.
<b>Competence 2.1.2.</b> Fulfills duties and obligations within the framework of ethical principles, rights, and legal responsibilities required by the profession.
<b>Competence 2.1.3.</b> Demonstrates determined behavior in providing high-quality healthcare while considering the patient's integrity.
<b>Competence 2.1.4.</b> Evaluates own performance in professional practices by considering own emotions and cognitive characteristics.
<b>COMPETENCY 2.2. Health Advocate</b>
<b>Competence 2.2.1.</b> Advocates for the improvement of healthcare service delivery by considering the concepts of social accountability and social responsibility in the protection and enhancement of community health.
<b>Competence 2.2.2.</b> Plans and implements service delivery, education, and counseling processes related to individual and community health, in collaboration with all stakeholders, for the protection and improvement of health.
<b>Competence 2.2.3.</b> Evaluates the impact of health policies and practices on individual and community health indicators and advocates for the improvement of healthcare quality.
<b>Competence 2.2.4.</b> Gives importance to protecting and improving own physical, mental, and social health and takes necessary actions for it.
<b>COMPETENCY 2.3. Leader-Manager</b>
<b>Competence 2.3.1.</b> Demonstrates exemplary behavior and leadership within the healthcare team during service delivery.
<b>Competence 2.3.2.</b> Utilizes resources in a cost-effective, socially beneficial, and compliant manner with regulations in the planning, implementation, and evaluation processes of healthcare services as the manager in the healthcare institution.
<b>COMPETENCY 2.4. Team Member</b>
<b>Competence 2.4.1.</b> Communicates effectively within the healthcare team and takes on different team roles as necessary.

<b>Competence 2.4.2.</b> Displays appropriate behaviors while being aware of the duties and responsibilities of healthcare workers within the healthcare team.
<b>Competence 2.4.3.</b> Works collaboratively and effectively with colleagues and other professional groups in professional practice.
<b>COMPETENCY 2.5. Communicator</b>
<b>Competence 2.5.1.</b> Communicates effectively with patients, their families, healthcare professionals, and other occupational groups, institutions and organizations.
<b>Competence 2.5.2.</b> Communicates effectively with individuals and groups who require a special approach and have different sociocultural characteristics.
<b>Competence 2.5.3.</b> Demonstrates a patient-centered approach that involves the patient in decision-making mechanisms during the diagnosis, treatment, follow-up, and rehabilitation processes.
<b>COMPETENCY AREA-3 / Professional and Personal Development</b>
<b>COMPETENCY 3.1. Scientific and Analytical Approach</b>
<b>Competence 3.1.1.</b> Plans and implements scientific research, as necessary, for the population it serves, and utilizes the results obtained, as well as those from other research, for the benefit of the community.
<b>Competence 3.1.2.</b> Accesses and critically evaluates current literature related to their profession.
<b>Competence 3.1.3.</b> Applies evidence-based medicine principles in the clinical decision-making process.
<b>Competence 3.1.4.</b> Uses information technologies to enhance the effectiveness of healthcare, research, and education activities.
<b>COMPETENCY 3.2. Lifelong Learner</b>
<b>Competence 3.2.1.</b> Manages effectively individual study processes and career development.
<b>Competence 3.2.2.</b> Demonstrates skills in acquiring, evaluating, integrating new information with existing knowledge, applying to professional situations, and adapting to changing conditions throughout professional career.
<b>Competence 3.2.3.</b> Selects the right learning resources to improve the quality of health care and organizes the learning process.

### 2024-2025 CURRICULUM OF PHASE III

CODE		THIRD YEAR	W	T	A	L	Y	E
MED	302	Introduction to Clinical Sciences	39	673		17		53
MED	303	Introduction to Clinical Practice III	32	11		22		5
MED	XXX	Free Elective Course <sup>1</sup> (SS)	14	28				2
Total Credits								60

The curriculum applies to 2024-2025 educational term. The duration of educational term for each year is shown in the table as total number of weeks. ECTS credits are the university credits of the courses in Yeditepe

University Faculty of Medicine Undergraduate Medical Education Program. 1 ECTS=25-30 hours of workload including independent study hours per average student. GPA and cGPA calculations are based on ECTS credits.

1 Free Elective Courses. Only one of the free elective courses provided by Faculty of Medicine can be selected in an educational year. Free elective courses provided by Faculty of Medicine in the first three years: MED 611

Medical Anthropology, MED 612 Creative Drama I, MED 613 Medical Humanities, MED 614 Personal Trademark Development, MED 615 Innovation Management, MED 616 Medical Management and New Services Design

Skills, MED 617 Personal Brand Management Skills, MED 618 Research and Development in Pharmaceutical Industry, MED 619 Entrepreneurship and Storytelling Techniques for Business Purposes, MED 620 Art, Culture and

Life Styles, MED 621 Epidemiological Research and Evidence Based Medicine, MED 622 Applications of Economics in Health Care, MED 623 Visual Presentation in Medicine, MED 624 Narrative Medicine MED 627 Presentation

of Medicine on Media, MED 628 Healthy Living, MED 629 Music and Medicine, MED 630 Health Law, MED 631 Creative Drama II, MED 632 Music Appreciation, MED 633 Communication with Hearing Impaired Patients in

Turkish Sign Language, MED 634 Case Based Forensic Science, MED 635 Advanced Level Communication with Hearing Impaired Patients in Turkish Sign Language, MED 636 Art Project, MED 637 Artistic Photography and

Composition

T: Theoretical, A: Application , L: Laboratory, Y: Yeditepe University Credit, E: ECTS Credit.

NC: Non-Credit Course, FS: Fall Semester, SS: Spring Semester, W: Weeks

\* Please see [https://med.yeditepe.edu.tr/sites/default/files/curriculum\\_2024-25\\_ytf\\_tr.docx](https://med.yeditepe.edu.tr/sites/default/files/curriculum_2024-25_ytf_tr.docx) for total curriculum of Med Fac.

## **DESCRIPTION and CONTENT of PHASE III**

Pathophysiological processes and pathological processes.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

## AIM and LEARNING OBJECTIVES of PHASE III

### AIMS

#### *In evidence based manner.*

1. **to remind** anatomy, histology and physiology of body systems,
2. **to convey** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 3.1. **to convey** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
  - 3.2. **to convey** knowledge on epidemiology,
  - 3.3. **to convey** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
  - 3.4. **to convey** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. **to convey** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. **to convey** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. **to convey** knowledge on biostatistical analysis,
7. **to convey** basic legal and ethical principles that should be followed in practice of medical profession,
8. **to equip with** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

### LEARNING OBJECTIVES

#### *At the end of this phase, student should be able to:*

- 1.0. **recall** anatomy, histology and physiology of body systems.
- 2.0. **list** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
- 3.0. **explain** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 4.0. at cellular or tissue level,
  - 4.1. **recognize** morphological characteristics,
  - 4.2. **show** basic pathological changes that occur in clinical conditions.
- 5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 5.1. **explain** mechanisms of destruction at molecule, cell, tissue, organ, system, multi-system and organismal level,
  - 5.2. **describe** structural and functional changes caused,
  - 5.3. **list** clinical courses in time.
- 6.0. **explain** mechanisms of emergence for frequently encountered;
  - 6.1. clinical complaints,
  - 6.2. symptoms,
  - 6.3. signs,
  - 6.4. laboratory and imaging findingsof clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 7.0. at multi-system level or related to a body system,
  - for healthy conditions in an individual or community with a request, or
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
  - health care processes,

- acquisition of subjective or objective data, information and knowledge required for clinical decision making,
- clinical decision making process,
- clinical decisions and
- clinical practices

which are required for management at primary health care service level.

7.1. practice of history taking and physical examination (*cardiovascular, pulmonary, gastrointestinal, gynecological, breast, neonatal, prepubertal/pubertal, neurological/neuropsychiatric, musculoskeletal*)

7.2. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)

7.3. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)

7.4. laboratory and imaging tests/examinations

7.4.1. based on laboratory disciplines/subdisciplines;

1. medical biochemistry tests:

i. (*venous blood collection*)

ii. (*thyroid function tests, diabetes tests*)

2. medical microbiology tests:

i. (*urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection, blood collection for culture*)

ii. (*urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture*)

3. medical pathology tests:

i. *Pap smear collection*

ii. *Pap smear*

4. other laboratory tests:

i. (*peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring*)

ii. (*pulmonary function tests, hematology tests for anemia, monitoring of drug therapy*)

5. radiological examinations: (*radiological examinations in gynecology, breast imaging, urology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign and malignant tumors of bones*)

6. nuclear medicine examinations: (*nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphy, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigraphy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy*)

7.4.3. point of care testing

a. based on laboratory disciplines/subdisciplines;

1. medical biochemistry tests: (*diabetes tests, cardiac markers, coagulation tests, blood gases*).

2. medical microbiology tests: (*urine strip/dipstick test, rapid screening (antigen/antibody tests)*)

3. other laboratory tests: (*hematology-peripheral blood smear examination, hematology-complete blood count*)

7.5. making preliminary diagnosis or definitive diagnosis decision

7.6. making non-intervention or intervention decision

7.7. practicing non-intervention or intervention

7.8. referral/transport of healthy individual or patient

## AIM and LEARNING OBJECTIVES of CLINICAL SCIENCES (MED 302)

### AIMS

#### *In evidence based manner:*

1. **to remind** anatomy, histology and physiology of body systems,
2. **to convey** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 3.1. **to convey** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
  - 3.2. **to convey** knowledge on epidemiology,
  - 3.3. **to convey** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
  - 3.4. **to convey** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of primary health care service,
4. **to convey** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. **to convey** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. **to convey** knowledge on biostatistical analysis,
7. **to convey** basic legal and ethical principles that should be followed in practice of medical profession,

### LEARNING OBJECTIVES

#### *At the end of this phase, student should be able to:*

- 1.0. **recall** anatomy, histology and physiology of body systems.
- 2.0. **list** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
- 3.0. **explain** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 4.0. at cellular or tissue level,
  - 4.1. **recognize** morphological characteristics,
  - 4.2. **show** basic pathological changes that occur in clinical conditions.
- 5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 5.1. **explain** mechanisms of destruction at molecule, cell, tissue, organ, system, multi-system and organismal level,
  - 5.2. **describe** structural and functional changes caused,
  - 5.3. **list** clinical courses in time.
- 6.0. **explain** mechanisms of emergence for frequently encountered;
  - 6.1. clinical complaints,
  - 6.2. symptoms,
  - 6.3. signs,
  - 6.4. laboratory and imaging findingsof clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 7.0. at multi-system level or related to a body system,
  - for healthy conditions in an individual or community with a request, or
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
  - health care processes,
  - acquisition of subjective or objective data, information and knowledge required for clinical decision making,
  - clinical decision making process,
  - clinical decisions and
  - clinical practiceswhich are required for management at primary health care service level.



- 7.1. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)
  - 7.2. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)
  - 7.3. laboratory and imaging tests/examinations
    - 7.3.1. based on laboratory disciplines/subdisciplines;
      1. medical biochemistry tests:
        - i. (*venous blood collection*)
        - ii. (*thyroid function tests, diabetes tests*)
      2. medical microbiology tests:
        - i. (*urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection-, blood collection for culture*)
        - ii. (*urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture*)
      3. medical pathology tests:
        - i. (*Pap smear collection*)
        - ii. (*Pap smear*)
    4. other laboratory tests:
      - i. (*peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring*)
      - ii. (*pulmonary function tests, hematology tests for anemia, monitoring of drug therapy*)
  - 7.3.2. imaging tests/examinations based on disciplines/subdisciplines:
    1. radiological examinations: (*radiological examinations in gynecology, breast imaging, urology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign and malignant tumors of bones*)
    2. nuclear medicine examinations: (*nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphy, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigraphy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy*)
  - 7.3.3. point of care testing
    - a. based on laboratory disciplines/subdisciplines;
      1. medical biochemistry tests: (*diabetes tests, cardiac markers-, coagulation tests-, blood gases*).
      2. medical microbiology tests: (*urine strip/dipstick test, rapid screening (antigen/antibody tests)*)
      3. other laboratory tests: (*hematology-peripheral blood smear examination, hematology-complete blood count*)
- 7.5. making preliminary diagnosis or definitive diagnosis decision
- 7.6. making non-intervention or intervention decision
- 7.7. referral/transport of healthy individual or patient

## **DESCRIPTION of INTRODUCTION to CLINICAL PRACTICE I, II and III (ICP-I,-II,-III) (MED 102, 202, 303)**

### **AIM of ICP PROGRAM**

The aim of Introduction to Clinical Practice Program is to equip the students with basic medical skills and attitudes, in areas such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying non –invasive or invasive procedures on the mannequins before encountering with real patients.

### **Description**

ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols.

### **Credit Facility**

This course has 5 ECTS credits for each of the first three years and all of the students are required to pass this course in order to pass the year.

### **Content of the ICP I-II-III**

First year medical students gain knowledge on First Aid approaches, Basic Knowledge on Infection Control and Standard Precautions, develop skills in Basic Life Support, Patient/Casualty Transportation and Bandaging Techniques regarding to First Aid and handwashing, wearing sterile gloves, wearing masks, assessing vital signs. They also acquire basic knowledge on communication and experience patient-doctor encounter with simulated patients (SP's)\*.

The second years ICP Program consist of modules like nasogastric intubation; bladder catheterization; intramuscular, subcutaneous, intradermal and intravenous injections; intravenous catheterization as well as intraarterial blood sampling.

In the third year medical students practice with SP's clinical skills like history taking and physical examination focused on body systems and in general and also mental examination. They also gain clinical skills such as suturing techniques and Advanced Cardiac Life Support.

### **Clinical Skills Laboratory**

The Clinical Skills Laboratory is designed for teaching and assessing students at undergraduate level (during the preclinical period from first-year to third year). The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on mannequins.

Each OSCE room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

### **\*Simulated Patients (SPs)**

The simulated patient encounters facilitate transfer of the gained theoretical knowledge to practice in simulated environments. SPs are usually, but not necessarily, lay people who are trained to portray a patient with a specific condition in a realistic way, sometimes in a standardized way (where they give a consistent presentation which does not vary from student to student). SPs are used for teaching and assessment of consultation and clinical/physical examination skills, in simulated teaching environments or in situ. (Cleland JA, Abe K, Rethans JJ. *The use of simulated patients in medical education: AMEE*

### **Assessment**

The Assessment procedure of ICP is given in the Assessment Table in this booklet.

### **Rules for Attendance of the Students**

Students are grouped into 4 or 5 and group lists are announced to the class and also displayed in the ICP Lab announcement board at the beginning of the year. Any changes to practical groups on a week by week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the deanary. Any change in sessions will only be accepted interchangeably with another student in another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).

Students are required to follow the rules of professional ethics in the laboratory at any time.

### **Program Evaluation**

Each Semester students are required to fill out a feedback form according the ICP Program. When an OSCE is conducted both students and faculty members complete a written evaluation of the event for the improvement of the course and OSCE.

## **AIM and LEARNING OBJECTIVES of INTRODUCTION to CLINICAL PRACTICE III (ICP-III) (MED 303)**

### **AIM**

The aim of ICP III Program is to equip Phase III students with basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of the medical profession.

### **LEARNING OBJECTIVES**

At the end of this phase, student should be able to:

#### **KNOWLEDGE**

1. **define** the basic terminology used in general and organ system specific physical examination.
2. **describe** the steps of history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal).
3. **describe** suture materials and choose the appropriate material.

#### **SKILLS**

1. **apply** Advanced Cardiac Life Support on an adult mannequin in accordance with the skill procedure.
2. **perform** sutures in accordance with the skill procedure.
3. **perform** history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal) on simulated patients or mannequins in accordance with the skill procedure.
4. **explain** the procedure to be carried out to the patient before the intervention.

#### **ATTITUDE**

1. **value** the importance of informed consent
2. **pay** attention to patient privacy
3. **value** the importance of not exceeding the limits of his/her own competency level.
4. **pay** attention to follow laboratory rules

**MED 303 ICP III COURSE 2024-2025 ACADEMIC PROGRAM**

DAY	HOUR	SUBJECT	LECTURER
30-Sep-24	14.00-16.50	<b>Ear-Nose-Throat Examination GROUP C</b>	Z. Alkan / M. Kılıçoğlu
<b>MONDAY</b>			
01-Oct-24	09.00-11.50	<b>Ear-Nose-Throat Examination GROUP D</b>	Z. Alkan / M. Kılıçoğlu
<b>TUESDAY</b>			
9-Oct-24	10.00-12.50	<b>Ear-Nose-Throat Examination GROUP A</b>	Z. Alkan / M. Kılıçoğlu
<b>WEDNESDAY</b>			
16-Oct-24	14.00-16.50	<b>Ear-Nose-Throat Examination GROUP B</b>	Z. Alkan / M. Kılıçoğlu
<b>WEDNESDAY</b>			
7-Nov-24	09:00-11:50	<b>Advanced Cardiac Life Support GROUP B</b>	T. Utku / Ö.Köner
<b>THURSDAY</b>			
8-Nov-24	14.00-16.50	<b>Advanced Cardiac Life Support GROUP A</b>	T. Utku / Ö.Köner
<b>FRIDAY</b>			
20-Nov-24	14.00-16.50	<b>Approach to a patient With Chest Pain GROUP A</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>WEDNESDAY</b>			
22-Nov-24	09.00-11.50	<b>Advanced Cardiac Life Support GROUP C</b>	T. Utku / Ö.Köner
<b>FRIDAY</b>			

	14.00-16.50	<b>Advanced Cardiac Life Support GROUP D</b>	
<b>25-Nov-24</b>	09.00-11.50	<b>Approach to a patient With Chest Pain GROUP B</b>	G.izbırak / S.Özdemir / D.Altıparmak
<b>MONDAY</b>	14:00-16:50	<b>Examination of Cardiovascular and Respiratory System GROUP C</b>	O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş
<b>26-Nov-24</b>	14:00-16:50	<b>Examination of Cardiovascular and Respiratory System GROUP D</b>	O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş
<b>TUESDAY</b>			
<b>4-Dec-24</b>	09.00-11.50	<b>Examination of Cardiovascular and Respiratory System GROUP B</b>	O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş
<b>WEDNESDAY</b>			
<b>5-Dec-24</b>	09.00-11.50	<b>Approach to a patient With Chest Pain GROUP C</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>THURSDAY</b>	14:00-16:50	<b>History Taking GROUP C</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>6-Dec-23</b>	9:00-11:50 14.00-16.50	<b>History Taking GROUP A</b> <b>Examination of Cardiovascular and Respiratory System GROUP A</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş
<b>FRIDAY</b>			
<b>11-Dec-24</b>	14:00-16:50	<b>Approach to a patient With Chest Pain GROUP D</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>WEDNESDAY</b>			
<b>13-Dec-24</b>	9:00-11:50	<b>History Taking GROUP B</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>FRIDAY</b>			

	14:00-16:50	<b>History Taking GROUP D</b>	G.izbırak / T. Sadıkoğlu / S.Özdemir / D.Altıparmak
<b>7-Jan-25</b>	15:00-17:50	<b>Physical Examination of Gastrointestinal System GROUP A</b>	A. Y. Kavurmacı / E. Bayar
<b>TUESDAY</b>			
<b>8-Jan-25</b>	09:00-11:50	<b>Physical Examination of Gastrointestinal System GROUP C</b>	A. Y. Kavurmacı / E. Bayar
<b>WEDNESDAY</b>			
<b>9-Jan-25</b>	09:00-11:50	<b>Physical Examination of Gastrointestinal System GROUP B</b>	A. Y. Kavurmacı / E. Bayar
<b>THURSDAY</b>			
<b>10-Jan-25</b>	09:00-11:50	<b>Physical Examination of Gastrointestinal System GROUP D</b>	A. Y. Kavurmacı / E. Bayar
<b>FRIDAY</b>			
<b>6-Feb-25</b>	09:00-11:50	<b>Follow-up of pregnancy &amp; stages of normal labour &amp; Gynecological examination, PAP smear obtaining GROUP A</b>	R.Attar./M.Yeşiladalı/M.Gökçe Koçer Yazıcı
<b>THURSDAY</b>			
<b>13-Feb-25</b>	09:00-11:50	<b>Follow-up of pregnancy &amp; stages of normal labour &amp; Gynecological examination, PAP smear obtaining GROUP B</b>	R.Attar./M.Yeşiladalı/M.Gökçe Koçer Yazıcı
<b>THURSDAY</b>			
<b>20-Feb-24</b>	09:00-11:50	<b>Follow-up of pregnancy &amp; stages of normal labour &amp; Gynecological examination, PAP smear obtaining GROUP C</b>	R.Attar./M.Yeşiladalı/M.Gökçe Koçer Yazıcı
<b>THURSDAY</b>			
<b>21-Feb-24</b>	09:00-11:50	<b>Follow-up of pregnancy &amp; stages of normal labour &amp; Gynecological examination, PAP smear obtaining GROUP D</b>	R.Attar./M.Yeşiladalı/M.Gökçe Koçer Yazıcı
<b>FRIDAY</b>			

<b>25-Feb-25</b> <b>TUESDAY</b>	14:00-16:50	<b>Clinical Breast Examination GROUP D</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>3-Mar-25</b> <b>MONDAY</b>	14:00-16:50	<b>Clinical Breast Examination GROUP B</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>4-Mar-25</b> <b>TUESDAY</b>	14:00-16:50	<b>Clinical Breast Examination GROUP C</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>10-Mar-25</b> <b>MONDAY</b>	14:00-16:50	<b>Clinical Breast Examination GROUP A</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>13-Mar-25</b>	09:00-16:50	<b>Physical Examination of the Newborn and Child Patient GROUP A-B-C-D</b>	Ç. Ayanoğlu / M. Berber
<b>THURSDAY</b>			
<b>28.04.2025 OSCE EXAM</b>			
<b>10.APR.2025</b>	09:00-11:50	<b>Neuropsychiatric assessment GROUP C</b>	R. Bilgen / O. Taycan / O. Zahmacioğlu / H. Atalay
<b>THURSDAY</b>			
<b>24-Apr-25</b>	10.00-12.50	<b>Neuropsychiatric assessment GROUP A</b>	R. Bilgen / O. Taycan / O. Zahmacioğlu / H. Atalay
<b>THURSDAY</b>	14.00-16.50	<b>General Physical Examination GROUP A</b>	A. Kurt
<b>29-Apr-25</b>	09.00-11.50	<b>Neuropsychiatric assessment GROUP D</b>	R. Bilgen / O. Taycan / O. Zahmacioğlu / H. Atalay
<b>TUESDAY</b>	14.00-17.50	<b>General Physical Examination GROUP B</b>	A. Kurt



<b>30-APR-25</b>	09.00-11.50	<b>General Physical Examination GROUP D</b>	A. Kurt
<b>WEDNESDAY</b>	14.00-17.50	<b>Neuropsychiatric assessment GROUP B</b>	R. Bilgen / O. Taycan / O. Zahmacioğlu / H. Atalay
<b>2-May-25</b>	09.00-11.50	<b>General Physical Examination GROUP C</b>	A. Kurt
<b>FRIDAY</b>			
<b>15-May-24</b>	09.00-11.50	<b>Physical examination of the musculoskeletal system GROUP A</b>	G. Meriç / B. Aksu
<b>THURSDAY</b>			
<b>21-May-25</b>	09.00-11.50	<b>Suturing Technique GROUP B</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>WEDNESDAY</b>			
	14:00-16:50	<b>Physical examination of the musculoskeletal system GROUP D</b>	G. Meriç / B. Aksu
<b>26-May-25</b>	09.00-11.50	<b>Suturing Technique GROUP C</b>	M. Ersan / E. Özer / B. Kağan Aysal
<b>MONDAY</b>	14:00-16:50	<b>Suturing Technique GROUP A</b>	
<b>28-May-25</b>	14:00-16:50	<b>Physical examination of the musculoskeletal system GROUP C</b>	G. Meriç / B. Aksu
<b>WEDNESDAY</b>			
<b>29-May-25</b>		<b>Suturing Technique GROUP D</b>	

<b>THURSDAY</b>	14:00-16:50		M. Ersan / E. Özer / B. Kağan Aysal
<b>30-May-25</b>			
<b>FRIDAY</b>	10:00-12:50	<b>Physical examination of the musculoskeletal system GROUP B</b>	G. Meriç / B. Aksu
<p style="text-align: center;"> <b>Beginning of ICP - III Sept 30, 2025 Monday</b>  <b>End of ICP - III May 30, 2025 Friday</b>  <b>Midterm Exam April 28, 2025 Monday</b>  <b>Make-up Exam May 23, 2025 Friday</b>  <b>Final Exam June 23-24, 2025 Monday-Tuesday</b>  <b>Incomplete Exam July 3, 2025 Thursday</b> </p>			

## **AIM and LEARNING OBJECTIVES of SCIENTIFIC RESEARCH and PROJECT COURSE- III**

### **Aim, objectives and explanation of course**

The Scientific Research and Project Course (SRPC) is crafted to offer medical students the chance to dive into research that is based on hypotheses, aiming to boost their analytical thinking abilities, increase their intellectual sharpness, and encourage a deeper sense of curiosity. It is designed to nurture top-notch skills in research, clinical, and teaching scholars. Students will explore various topics across different fields, including the biomedical sciences, clinical sciences, humanities, arts, and more. Additionally, students will learn and implement key professional values, ethical standards, communication strategies, and teamwork skills throughout their research journey.

The purpose of the course is to introduce students to the scientific inquiry process, showing them how to pose questions that can be answered and the methods needed to find the right answers. The SRPC is integrated into the medical school education and curriculum. The program is implemented along the longitudinal corridor, covering the first three phases/classes of the school. The objectives of the course include:

- Identify a significant scientific or clinical question to explore.
- Review, analyze, and use scientific literature related to the selected question.
- Create a project hypothesis based on the latest research and theories in the scientific area.
- Discover suitable methods to tackle the question, following established standards in the relevant disciplines.
- Plan, carry out, and analyze the outcomes of their own projects, focusing on the question and hypothesis.
- Determine how the project connects to medicine and healthcare.
- Express ideas clearly through speaking and writing.
- Uphold ethical standards and professionalism throughout the project.

The SRPC is designed to ignite curiosity, enhance understanding, and encourage research activities among students in their undergraduate medical studies. To accomplish these objectives, the SRPC program is structured into three main parts:

1. A classroom-based part that includes lectures, small group study&discussions, and collaborative learning activities,
2. Guidance from teachers in acquiring the abilities needed to create and articulate a research question, a related hypothesis, and the approach to carry out the research,
3. A student project.

### **Instructional methods**

Team-based learning (TBL) will be used as an active learning strategy for SRPC to promote critical thinking, knowledge application, teamwork, and collaboration. Each TBL session should include pre-reading materials for students to review before attending the class. These materials should help students grasp the fundamental ideas of the session. Instructors will outline the goals of the session before or during the readings and create tests to assess these goals. When students arrive for the TBL session, they will take an Individual Readiness Assurance Test (IRAT). This test ensures each student has understood the assigned readings and is usually a true/false/multiple-choice quiz (20% of final grade). Students may also have a Team Readiness Assurance Test (TRAT) at the start of class to address any misunderstandings or issues (20% of final grade). The instructor will look for any misunderstandings and promote discussions, but will not provide answers or solutions, instead focusing on explaining

complex concepts as necessary. Students will be responsible for their own homework (60% of final grade), as their individual scores will be factored into their final score for SRPC.

**ASSESSMENT PROCEDURE:**

For the assessments of the medical students for the SRPC, it is calculated out of 100 points; 60% will be graded on Assignment 1 (scientific project proposal-I) at the end of the first semester (**Jan 17, 2025**) and 60% will be graded on Assignment 2 (scientific project proposal-II) at the end of the second semester (**Jun 13, 2025**).

	Percentage of final grade
Individual Readiness Assurance Test (IRAT)	20%
Team Readiness Assurance Test (TRAT)	20%
Homework	60%

The constraints of the scientific project proposal assignment will be discussed individually during Small Group Study hours, and during the year small group discussion hours on the program will be used to prepare the individual/group proposals. *The application form template* can be used to create your own *project proposal and scientific project proposal form must be filled in in all its parts.*

The Scientific Research and Project Course III has 3% contribution to Term Score (TS). Please note that you may only attend Small Group Study hours in the assigned group hours. A list of groups will be published during the first week of the term.

Turning in assignments on time: Any assignments given by the instructor should be turned in on the date and time decided by the instructor. Assignments turned in after the deadline will not be accepted and students will receive zero points.

Note: Instructor has right to change the assignments and assesment portions of the assignments.

## ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbreviations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores\*:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Research and Project Course Score (SRPCS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

\* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		FSAQ: Fill-in-the-Blank Short Answer Questions	MuE	CS
Competency-based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance-based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SRPCS

Exams Information (MED 302, MED 303)	
<b>CE</b>	For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
<b>FE</b>	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
<b>ICE</b>	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
<b>MUE<sub>ics</sub></b>	MUE will be held only twice in a term. MUE consists of FSAQs. MUE content will be developed by the coordination committees.

<b>Scores Information (MED 302, MED 303)</b>	
<b>CS</b>	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
<b>CMS</b>	= Average of CSs
<b>ICPS</b>	= (50% Midterm) + (50% Final)
<b>SRPCS</b>	= Score information is shown in below Scientific Research and Project Course-III page.
<b>FES</b>	= Final Exam Score
<b>ICES</b>	= Incomplete Exam Score
<b>TS</b> <i>for students, who are exempted from FE</i>	= 97% of CMS + 3% of SRPCS
<b>TS</b> <i>for students, who are not exempted from FE</i>	= 97% of (60% of CMS + 40% of FES or ICES) + 3% of SRPCS

<b>Pass or Fail Calculations of the Courses</b>	
<b>INTRODUCTION to CLINICAL SCIENCES (ICS) III (MED 302)</b>	
<i>Pass; TS ≥ 60</i>	
<i>Fail; FES &lt; 50 (barrier point), ICES &lt; 50 (barrier point), or/and TS &lt; 60</i>	
<i>The student is exempted from FE, if the CMS is ≥ 80 and all CSs are ≥ 60</i>	
<i>The FE and ICE barrier point is not applied to the students whose all CSs are ≥ 60</i>	
<b>INTRODUCTION to CLINICAL PRACTICE (ICP) III (MED 303)</b>	
<i>Pass; ICPS ≥ 60</i>	
<i>Fail; ICPS &lt; 60</i>	

*The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.*

### **Definitions of the Assessment Methods and Question Types**

**MCQ** consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

**EMQ** are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

**MEQ** is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

**FSAQ**, Fill-in-the-Blank Short Answer Questions are typically composed of a brief prompt that demands a written answer that varies in length from one or two words to a sentence.

**OSCE** describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

**Grades**

A letter grade is given to the students as a success grade, from the numerical values of the grades given by the relevant teaching staff for each course they take, taking into account the practice, laboratory and similar studies in the semester and examinations and academic activities.

Grades and Letter grades are shown for MED coded courses\* in the following table:

<b>Grades</b>	<b>Letter Grades</b>
90-100	AA
80-89	BA
70-79	BB
65-69	CB
60-64	CC
59 or less	FF (Fail in the context of "Pass or Fail Calculations of the Courses" table pp.31)
0	FA (Fail due to nonattendance to the courses)

## **RULES FOR COURSE ATTENDANCE OF THE STUDENTS**

### **General Rules:**

Students are required to attend the all theoretical and practical sessions such as laboratory work, discussions, seminars, area and clinical studies of courses for the term they are enrolled in. Students whose absenteeism in the theoretical and/or practical sessions exceeds 20% are not admitted to term final and incomplete examinations of the courses.

### **Phase I, II, and III:**

#### **BMS I, BMS II, ICS course committees**

A student is required to attend a committee in full. A student who fails to fulfill the attendance requirements is not admitted to the committee examination, and is deemed to have failed that committee. The absenteeism of a student, whose absenteeism does not exceed 20% of a committee and who has a reason considered justified and valid, may be accepted. However, a student whose absenteeism in the theoretical and/or practical sessions in a committee exceeds 20% but whose excuse is accepted by the Board of Directors, is admitted to the make-up examination of the related committee if his/her absenteeism does not exceed 20% of the total number of the course hours covering/including all the committees throughout the term.

#### **ICP I,II,III courses**

A student whose absenteeism exceeds 20% of the theoretical and/or laboratory sessions in the program until the midterm exam date will not be admitted to the ICP Mid-Term exam (MCQ and/or OSCE). However, a student whose absence exceeds 20%, but whose excuse is accepted by the Board of Directors, is admitted to the make-up examination of the ICP Mid-Term exam, if his/her absenteeism does not exceed 20% of the total course hours during the term.

**For more information:** [https://yeditepe.edu.tr/sites/default/files/2023-02/yeditepe\\_university\\_faculty\\_of\\_medicine\\_training-instruction\\_and\\_examination\\_regulation.pdf](https://yeditepe.edu.tr/sites/default/files/2023-02/yeditepe_university_faculty_of_medicine_training-instruction_and_examination_regulation.pdf)



## EXAM RULES

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.
- **Other Activities Requiring Disciplinary Action-**
  - Students must not give or receive assistance of any kind during the exam.
  - Gaining access to exam questions before the exam.
  - Using an unauthorized calculator or other mechanical aid that is not permitted.
  - Looking in the exam book before the signal to begin is given.
  - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
  - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
  - Having access to or consulting notes or books during the exam.
  - Looking at or copying from another student's paper.
  - Enabling another student to copy from one's paper.
  - Talking or otherwise communicating with another student during the exam or during the read through period.
  - Disturbing other students during the exam.
  - Consulting other persons or resources outside the exam room during the exam.
  - Copying questions or answers either on paper or with an electronic device to take from the exam room.
  - Taking an exam book or other exam materials from the exam room.
  - Taking an exam in place of another student.
  - Arranging to have another person take an exam for the student.
  - Disobeying to the conduct of supervisor during the exam.
  - Disclosing the contents of an exam to any other person.
  - Failing to remain in the exam room for a given period of time by the supervisors.
  - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may lose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

## PROGRESS TEST

Progress test (PT) is used to assess students on topics from all medical disciplines. As an assessment tool in medical education, the PT offers some distinctive characteristics that set it apart from other types of assessment. It is administered to all students in the medical program at the same time and at regular intervals (usually twice a year) throughout the entire academic program. The test samples the complete knowledge domain expected that a student to have on graduation, regardless of which grade the student is at. The scores provide beginning-to-end and curriculum-independent assessments of the objectives for the entire medical program. The purpose of the PT as a formative or summative test is variably used across institutions.

In YUTF, PT is applied according to the following principles and rules.

### Purpose

- In YUTF, PT is used for formative purposes.
- PT is conducted to allow students to see their progress in knowledge levels throughout their medical education.

### Obligation

- PT is mandatory for all students.

### Frequency and Timing

- PT is performed twice a year.
- Each student will have received a total of 12 PTs by the end of the Phase 6.
- In a year; the first PT is done in the middle and the second PT is done at the end of the term.
- PT dates are announced by the Phase Coordinator.

### Implementation

- PT is performed online via EYS.

### Content

- PT consists of 200 multiple choice questions.
- 100 of them are related to the preclinical period and the rest 100 are related to the clinical period.
- The ratio of the questions to be asked according to the disciplines is announced to the students before PT.
- All students from 1st to 6th Phase are to answer the same questions.

### Feedback

- A report is sent to each student after each PT.
- The report includes how many questions the student answered correctly in each discipline and their progress against the previous PT.
- Students can also view their ranking within their class and within the entire school.

### Benefits

- PT gives students the opportunity to see their progress throughout their medical education.
- PT provides opportunities for students to prepare for other exams (Committee, Clerkship, TUS, USMLE, etc.).
- As questions are often enhanced with a real life problem, PT contributes to students' problem-solving skills. This question type is preferred in TUS, especially USMLE and other similar exams.

***\*Participation in the Progress Test (PT) is compulsory. Students who do not complete the PT will not be eligible to progress to the next phase.***

## AIM OF FREE ELECTIVE COURSES

Free elective courses aim to add complementary educational experiences to the medical school curriculum in order to improve comprehension of biopsychosocial approach of medical students, besides offering an opportunity to extend knowledge of interest in specific domains.

The following courses (2 ECTS credits each) will be offered in Spring semester. Each student has to choose one of these elective courses. The selection and enrollment procedure will be announced by the phase coordinator.

### List of Free Elective Courses

Code	Subject
MED 611	Medical Anthropology
MED 612	Creative Drama I
MED 613	Medical Humanities
MED 614	Personal Trademark Development
MED 615	Innovation Management
MED 616	Medical Management and New Services Design Skills
MED 619	Entrepreneurship and Storytelling Techniques for Business Purposes
MED 620	Art, Culture and Life Styles
MED 621	Epidemiological Research and Evidence Based Medicine
MED 622	Application of Economics in Health Care
MED 623	Visual Presentation in Medicine
MED 627	Presentation of Medicine on Media
MED 628	Healthy Living: The Milestones of the Life for Performance Management
MED 629	Music and Medicine
MED 630	Health Law
MED 631	Creative Drama II
MED 632	Music Appreciation
MED 633	Communication with Hearing Impaired Patients in Turkish Sign Language
MED 634	Case Based Forensic Sciences
MED 635	Advanced Level Communication with Hearing Impaired Patients in Turkish Sign Language
MED 636	Art Project
MED 637	Artistic Photography and Composition

Please visit the website for more information: <https://med.yeditepe.edu.tr/en/academic-program-booklets> (You can reach Elective Courses Guide)

## SPECIFIC SESSIONS / PANELS

### INTRODUCTORY SESSION

#### **Aim of the session:**

The session provides basic information about Yeditepe University Faculty of Medicine Undergraduate Medical Education Program (YUFM/UG-ME) and the educational phase relevant to the students. This session orients the students to the program and the phase.

#### **Objectives of the Session:**

1. To provide basic information about the YUFM/UG-ME.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

#### **Rules of the Session:**

1. The session will be held in two types, conducted by Phase Coordinator and Committee Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee.
3. Students should attend the session.

#### **Implementation of the Session:**

In the first type, Phase Coordinator will present brief information on the following topics:

- Organizational Chart of Yeditepe University Faculty of Medicine Undergraduate Program (YUFM/UG-ME), Work Descriptions and Introduction of Committees Members,
- Directives on YUFM/UG-ME,
- YUFM/UG-ME Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I and Phase II)
- Assessment Procedure
- Grade Point Average, Cumulative Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

In the second type, Committee Coordinator will present brief information on the following topics:

- Learning Objectives of the Committee
- Academic Program of the Committee
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

## **COMMITTEE EVALUATION SESSION**

### **Aim of the Session:**

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the educational program in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

### **Objectives of the Program Evaluation Session** are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

### **Process:**

The total duration of the session is 90 minutes and the session consists of two parts. The first part (30 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the second part (60 minutes) committee exam questions will be reviewed and discussed by students and faculty.

### **Rules of the Committee Evaluation Session:**

1. The **Committee Evaluation Session** will be held on the last day of each committee after the committee exam.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. The faculty members who had contributed questions in the committee exam should attend the session.
5. Students must comply with the feedback rules while giving verbal feedback and all participants shall abide by rules of professional ethics.

## **PROGRAM IMPROVEMENT SESSION**

### **Aim:**

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

### **Objectives:**

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

### **Rules:**

1. Program improvements session will be implemented once a year. The implementation will be performed at the beginning of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

### **Implementation:**

#### **Before the Session**

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

#### **During the Session**

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

**Process:** The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

#### **After the Session**

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (<http://med.yeditepe.edu.tr>).

## MULTIDISCIPLINARY CASE DISCUSSION PANEL

### **Aim:**

The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

### **Objectives:**

1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importance of multidisciplinary study in the resolution of clinical cases.

### **Implementation:**

#### **Before the Panel**

1. Case/cases that will be discussed in the panel will be chosen by a multidisciplinary team, in compliance with committee learning objectives.
2. The resources to analyze the cases will be specified by multidisciplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

#### **During the Panel**

6. Cases will be shared visually with students by the multidisciplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisciplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the committee learning objectives in the context of cases.

**Process:** The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisciplinary team. The second part (20 minutes), covers students' questions and discussion.

#### **After the Panel**

9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisciplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisciplinary team.

## INDEPENDENT LEARNING

### Description:

“Independent learning” is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one’s learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

### Aim:

The aim of this instructional strategy is to develop the students’ ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

### Objectives:

*With this instructional strategy, students will develop;*

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

### Rules:

1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students’ academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

### What a student should do for learning independently?

1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called “independent learning hour” for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.
8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.



## COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
<b>MED 302</b>	INTRODUCTION to CLINICAL SCIENCES	<b>Lectures/Sessions/Panels:</b> Room Number: B311, Base Floor, Medical Faculty Block, Yeditepe University Campus. <b>Microbiology Laboratory:</b> Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. <b>Pathology Laboratory:</b> Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE	<b>ICP-CSL:</b> Room Number: 442, Ground Floor, Medical Faculty Block, Yeditepe University Campus. <b>YH:</b> Yeditepe University Hospital.

**Yeditepe University Campus Address:** İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

**Yeditepe University Hospital Address:** İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

\* Elective courses locations will be announced later.

## RECOMMENDED TEXTBOOKS

NO	DEPARTMENT	TEXTBOOK	AUTHOR	PUBLISHER
1	BIOMEDICAL ETHICS & DEONTOLOGY	Medical Law, Ethics, & Bioethics for the Health Professions, 2012	Marcia Lewis, Carol D. Tamparo.	F.A. Davis Publishing House
		Medical Ethics, 2013	Michael Boylan	Wiley-Blackwell Publishing House
2	BIOSTATISTICS	Principles of Biostatistics, 2000	Pagano, Marcello, Gauvreau, Kimberlee	Duxbury Press
		Primer of Biostatistics. 7th Edition, 2011	Glantz, Stanton A	McGraw Hill Professional
3	INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Medical Microbiology with STUDENT CONSULT Online Access. 8th Edition, 2016.	Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.	
4	MEDICAL GENETICS	Emery's Elements of Medical Genetics. 14th Edition.	Turnpenny, Peter D, Ellard, Sian.	Churchill Livingstone
5	NEUROSURGERY	Microneurosurgery, Volume I to Volume V, Thieme Kindle Edition	Mahmut Gazi Yasargil	
		Neurology and Neurosurgery Illustrated, 5th Edition	Kenneth W. Lindsay PhD FRCS, Ian Bone FRCP FACP, Geraint Fuller MD FRCP	
		Handbook of Neurosurgery	Mark S. Greenberg	
6	PHARMACOLOGY	Lippincott's Illustrated Review of Pharmacology. 6th ed, 2015	Harvey, Richard A.	Wolters Kluwer Health
		Katzung's Basic & Clinical Pharmacology. 14th Edition. 2017	Katzung, Bertram G., Masters, Susan B., Trevor Anthony J.	McGraw Hill Companies
		Goodman&Gilman's The Pharmacological Basis of Therapeutics. 13th Edition.2017	Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn	McGraw Hill Companies
7	ORTHOPEDIC SURGERY	Ortopedik Fizik Muayane	Uğur Şaylı	Güneş Tıp Kitapevi
		Review of Orthopaedics 6th edition	Mark D. Miller	
		AAOS Comprehensive Orthopaedic Review 2nd edition	Martin I. Boyer	
8	PATHOLOGY	Robbins Basic Pathology. 9th edition,2013	Abbas Aster, Kumar.	Saunders, Elsevier Inc.
9	PSYCHIATRY	Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011	Öztürk O	
		Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009,	Sadock BJ, Sadock VA, Ruiz P.	Lippincott Williams & Wilkins, PA, USA
		Neuroscience. 5. Ed. 2012	Purves D, Augustine GJ, Fitzpatrick D.	Sinauer Assoc, Mass, USA.
10	GENERAL SURGERY	Schwartz's Principles of Surgery, 10th edition, July 16, 2014	Brunicaardi, F	
11	UROLOGY	Campbell-Walsh Urology, 11th Edition 4-Volume Set. 2016	Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD	Elsevier
12	PATHOPHYSIOLOGY	Harrison's Principles of Internal Medicine, 21e; Joseph Loscalzo, Anthony Fauci, (you can read this book from <a href="https://accessmedicine.mhmedical.com">https://accessmedicine.mhmedical.com</a> ; access provided by Yeditepe University)	Dennis Kasper, Stephen Hauser, Dan Longo, J. Larry Jameson	McGraw Hill
		Pathophysiology of Disease: An Introduction to Clinical Medicine, 8e. (you can read this book from <a href="https://accessmedicine.mh">https://accessmedicine.mh</a>	Gary D. Hammer, Stephen J. McPhee, Lange	McGraw Hill

		medical.com; access provided by Yeditepe University)		
		Huppert's Notes: Pathophysiology and Clinical Pearls for Internal Medicine, (you can read this book from <a href="https://accessmedicine.mhmedical.com">https://accessmedicine.mhmedical.com</a> ; access provided by Yeditepe University)	Laura A. Huppert.	McGraw Hill
13	IMMUNOLOGY	Basic Immunology, Functions and Disorders of the Immune System, 7th edition 2023	Abul K Abbas et al.	Elsevier
		Clinical Immunology, 6th edition 2022	Robert Rich et al.	Elsevier

**COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM**

**DISTRIBUTION of LECTURE HOURS**

**September 9, 2024 – November 1, 2024**

**COMMITTEE DURATION: 8 WEEKS**

COURSES							
	INTRODUCTION to CLINICAL SCIENCES	ABBR	THEO.	PRAC./LAB.	SMALL GROUP DISCUSSION	DISCUSSION	TOTAL
	DISCIPLINE/COMPONENTS						
<b>MED 302</b>	INFECTIOUS DISEASES	ID	12	0	0	0	12
	MEDICAL MICROBIOLOGY	MM	17	1H+4GrX1H	0	0	19
	PHARMACOLOGY	PC	21	0	0	0	21
	PATHOLOGY	PT	14	0	0	2	16
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	12	0	0	0	12
	HEMATOLOGY	HEM	11	0	0	0	11
	PUBLIC HEALTH	PH	8	0	0	0	8
	IMMUNOLOGY	IMM	6	0	0	0	6
	MEDICAL GENETICS	MG	5	0	0	0	5
	PEDIATRICS	PED	4	0	0	0	4
	PATHOPHYSIOLOGY	PP	6	0	0	0	6
	PHYTOTHERAPY	PHY	3	0	0	0	3
	BIOSTATISTICS	BS	3	0	0	0	3
	ONCOLOGY	ONC	3	0	0	0	3
	FAMILY MEDICINE	FM	2	0	0	0	2
	EMERGENCY MEDICINE	EM	1	0	0	0	1
	MEDICAL BIOLOGY	MB	1	0	0	0	1
	INTERDISCIPLINARY (ID, PT, HEM)	MCDP	0	0	0	2	2
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC	2	0	4Gr X 2H	0	4
	<b>TOTAL</b>			131	2	2	4
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III		4Gr X 3H			3
<b>INDEPENDENT LEARNING HOURS</b>							<b>165</b>

**Coordination Committee**

<b>HEAD</b>	Meral Sönmezoğlu, MD, Prof.
<b>SECRETARY</b>	Başak Aru, PhD, Assist. Prof.
<b>MEMBER</b>	Ece Genç, PhD, Prof.
<b>MEMBER</b>	Güner Söyletir, MD, Prof.
<b>MEMBER</b>	Bala Başak Öven, MD, Prof.

**COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM  
LECTURERS**

<b>MED 302 INTRODUCTION to CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof.
MEDICAL MICROBIOLOGY	Güner Söyletir, MD, Prof. Aynur Eren Topkaya, MD, Prof. Pınar Çıragil, MD, Prof. Sibel Ergüven, MD, Prof. Nilgün Çerikçioğlu, MD, Prof. Lab: Selvi Duman Bakirezer, PhD. Lab: Zehra Kipritçi, PhD.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof Ahmet Cenk Andaç, PhD. Assist. Prof
PATHOLOGY	Aydın Sav, MD, Prof. Ezgi Hacıhasanoğlu, MD, Assist. Prof
HEMATOLOGY	Figen Atalay, MD, Assoc.Prof. Elif Birtaş Ateşoğlu, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof Fulya Coşkunol, MD
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Assist. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Prof.
FAMILY MEDICINE	Tümay Sadıkoğlu, MD. Assist. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist Prof.
BIOSTATISTICS	Çiğdem Keleş, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assoc. Prof.
PHYTOTHERAPY	Etil Güzelmeriç, PhD, Assoc. Prof. Rima Konya Konuk, PhD, Instructor
ONCOLOGY	Bala Başak Öven, MD, Prof. Serkan Çelik, MD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
MEDICAL BIOLOGY	Ayşe Özer, PhD, Prof.
<b>OTHER COURSES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.

<b>MED 303 INTRODUCTION to CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Zeynep Alkan, MD, Assoc. Prof. M. Kılıçoğlu, MD.

## **COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM**

### **AIMS and LEARNING OBJECTIVES**

#### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in infectious and hematological clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to infectious and hematological clinical conditions, this committee aims to convey necessary knowledge on ethical problems, biostatistical knowledge required in design of medical research and to convey necessary knowledge on genetic basis of clinical conditions, immune response and phytotherapy.

#### **LEARNING OBJECTIVES OF INFECTIOUS DISEASES**

In evidence-based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency, at the primary health care level; at the end of this committee, the student should be able to:

- I1. to recall knowledge on structures of agents that cause infectious clinical conditions
- I2. to define pathogenesis of mechanisms of agents that cause infectious clinical conditions
- I3. to explain epidemiology of infectious clinical conditions
- I4. to explain prevention of infectious clinical conditions, and protection or improvement of health against these conditions
- I5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions
- I6. to explain knowledge together with performance measures on health care processes, clinical decision-making process, clinical decisions and clinical practices required for managing infectious clinical conditions
- I7. to explain fundamental knowledge on pharmacology of drugs used in infectious clinical conditions.
- I8. to define ethical problems encountered in health care service and utilization, and on principles of solutions
- I9. to convey necessary knowledge on genetic basis of clinical conditions
- I10. to define biostatistical knowledge required in design of medical research (research design, planning, medical research)

#### **LEARNING OBJECTIVES OF HEMATOPOIETIC SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency related to Hematopoietic System, at the primary health care level; at the end of this committee, the student should be able to:

- H1. to recall knowledge on histology and physiology of hematopoietic system
- H2. to define etiopathogenesis of clinical conditions
- H3. to explain epidemiology of clinical conditions related to hematopoietic system
- H4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system
- H5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions related to hematopoietic system
- H6. to explain together with performance measures on health care processes, clinical decision-making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system
- H7. to convey knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system
- H8. to define basic knowledge on phytotherapy
- H9. to define comparative biostatistical analysis of study groups

**COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
I1-I6, H1-H6	ID	M. Sönmezoğlu	8	4	4	16
I1-I5	MM	G. Söyletir	12	5	5	22
		P. Çıragil				
		N. Ç. Çerikçioğlu				
		S. Ergüven				
I7-H7	PC	E. Genç	14	6	6	26
		A. C. Andaç				
		E.N. Özdamar				
I2, H2	PT	A. Sav	10	4	4	18
		E.Hacıhasanoğlu				
I8	BED	E. Vatanoğlu Lutz	8	4	4	16
H2,H5,H6	HEM	F. Atalay	8	3	3	14
		E. B. Ateşoğlu				
I3-I4, H3	PH	H. A.Taşıykan	6	3	3	12
I5, H5	IMM	G. Y. Demirel	4	2	2	8
I9	MG	A. Ç. Kuşkucu	4	2	2	8
I2, H2	PP	M. Kaçar	4	2	2	8
I2-I6, H2-H6	PED	S. Kemahlı	3	1	1	5
		F.Coşkunol				
H8	PHY	E. Güzelmeriç	2	1	1	4
		R. Konya Konuk				
I10, H9	BS	Ç. Keleş	2	1	1	4
H5	ONC	B. B. Öven	2	1	1	4
		S. Çelik				
H6-I6	FM	T. Sadıkoğlu	1	0	0	1
I5	EM	M. F. Çelikmen	1	0	0	1
H1	MB	A. Özer	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>39</b>	<b>39</b>	<b>168</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0 -12.0, H7, H8	ID	M. Sönmezoğlu	2	-	-	2
H1 – H7	HEM	F. Atalay/E.B.Ateşoğlu	2	-	-	2
4.0.,5.0, H2	PT	A. Sav	1	-	-	1
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts:points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*39** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM**

**WEEK I / 9 – 13 Sep 2024**

	<b>Monday 9-Sep--2024</b>	<b>Tuesday 10-Sep--2024</b>	<b>Wednesday 11-Sep--2024</b>	<b>Thursday 12-Sep--2024</b>	<b>Friday 13-Sep--2024</b>
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
11.00- 11.50	Independent Learning	<b>Lecture</b> Introduction to Antimicrobial Chemotherapy <i>E. Genç</i>	Independent Learning	Independent Learning	Independent Learning
12.00- 12.50	Introduction to Phase III	<b>Lecture</b> Vancomycin & Other Cell Wall Synthesis Inhibitors <i>E. Genç</i>	Independent Learning	Independent Learning	Independent Learning
12.50 - 14.00	LUNCH BREAK				
14.00- 14.50	<b>Lecture</b> Pathophysiology of Infectious Diseases I <i>M. Kaçar</i>	<b>Lecture</b> Research Project Components-I SRPC <i>A. Yaba Uçar</i>	Independent Learning	<b>Lecture</b> Opportunistic parasitic infections <i>S. Ergüven</i>	<b>Lecture</b> $\beta$ Lactam Antibiotics I <i>E. Genç</i>
15.00- 15.50	<b>Lecture</b> Pathophysiology of Infectious Diseases II <i>M. Kaçar</i>	<b>Lecture</b> How to Write a Research Project?-I SRPC <i>A. Yaba Uçar</i>	<b>Lecture</b> Hospital Infection <i>M. Sönmezoğlu</i>	<b>Lecture</b> Tissue and blood protozoa <i>S. Ergüven</i>	<b>Lecture</b> $\beta$ Lactam Antibiotics I <i>E. Genç</i>
16.00- 16.50	<b>Lecture</b> Pathophysiology of Infectious Diseases III <i>M. Kaçar</i>	Independent Learning	<b>Lecture</b> Febril Neutropenia <i>M. Sönmezoğlu</i>	<b>Lecture</b> Tissue and blood protozoa <i>S. Ergüven</i>	Independent Learning
17.00-17.50	Independent Learning	Independent Learning	<b>Lecture</b> Infections in Immunocompromised Host <i>M. Sönmezoğlu</i>	Independent Learning	Independent Learning

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.



**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM**

**WEEK II / 16 – 20 Sep 2024**

	<b>Monday 16-Sep--2024</b>	<b>Tuesday 17-Sep--2024</b>	<b>Wednesday 18-Sep--2024</b>	<b>Thursday 19-Sep--2024</b>	<b>Friday 20-Sep--2024</b>
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50	<b>Lecture</b> Retroviral Infections and HIV G. Söyletir	Independent Learning	Independent Learning	Independent Learning	<b>Lecture</b> Introduction to Anemias in Childhood S. Kemahli
11.00- 11.50	<b>Lecture</b> Opportunistic Mycoses N. Çerikçioğlu	<b>Lecture</b> Molecular Basis of Hemoglobinopathies A.Özer	<b>Lecture</b> Laboratory Diagnosis of infectious diseases G. Söyletir	Independent Learning	<b>Lecture</b> Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) S. Kemahli
12.00- 12.50	<b>Lecture</b> Opportunistic Mycoses N. Çerikçioğlu	<b>Lecture</b> Clinical aspects of antimicrobial susceptibility testing G. Söyletir	<b>Lecture</b> Laboratory Diagnosis of infectious diseases G. Söyletir	<b>Microbiology Laboratory</b> Laboratory methods in Mycology G. Söyletir, P. Çiragil, A.E Topkaya Z. Kipritçi, S.D Bakirezer	<b>Lecture</b> Hemophilia and other Coagulopathies in Childhood S. Kemahli
12.50 - 14.00	LUNCH BREAK				
14.00- 14.50	<b>Lecture</b> Hodgkin's Lymphoma E. Hacıhasanoğlu	<b>Lecture</b> Pathology of Myeloproliferative Diseases I E. Hacıhasanoğlu	<b>Lecture</b> Pathology of Bone Marrow-1 E. Hacıhasanoğlu	Group A	Independent Learning
15.00- 15.50	<b>Lecture</b> Lymphoreactive Disease E. Hacıhasanoğlu	<b>Lecture</b> Pathology of Myeloproliferative Diseases II E. Hacıhasanoğlu	<b>Lecture</b> Pathology of Bone Marrow-2 E. Hacıhasanoğlu	Group B	Independent Learning
16.00- 16.50	<b>Lecture</b> Pathology of Spleen E. Hacıhasanoğlu	Independent Learning	Independent Learning	Group C	Independent Learning
17.00-17.50	Independent Learning	Independent Learning	Independent Learning	Group D	Independent Learning

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM**  
**WEEK III / 23-27 Sep 2024**

	<b>Monday 23-Sep--2024</b>	<b>Tuesday 24-Sep--2024</b>	<b>Wednesday 25-Sep--2024</b>	<b>Thursday 26-Sep--2024</b>	<b>Friday 27-Sep--2024</b>
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Beneficence and Non-Maleficence E.Vatanoğlu Lutz	<b>Lecture</b> Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu	<b>Lecture</b> Case Discussion on Immunity to Infection G. Yanikkaya Demirel/A. Aral	<b>Lecture</b> Genetics of Oncology I A.Ç. Kuşkucu
<b>10.00- 10.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Transplantation E.Vatanoğlu Lutz	<b>Lecture</b> Inherited Immune System Disorders A. Ç. Kuşkucu	<b>Lecture</b> Case Discussion on Immunity to Infection G. Yanikkaya Demirel/A. Aral	<b>Lecture</b> Genetics of Oncology II A.Ç. Kuşkucu
<b>11.00- 11.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Principles of Autonomy and Informed Consent E.Vatanoğlu Lutz	<b>Case Discussions</b> Pathology Tissue Response to Infections A. Sav	<b>Lecture</b> Immunomodulators A. C. Andaç	<b>Lecture</b> Macrolides E. N. Özdamar
<b>12.00- 12.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Justice in Medicine E.Vatanoğlu Lutz	<b>Case Discussions</b> General Review of Pathology of Infections Disease A. Sav	<b>Lecture</b> Antimycobacterial Drugs A.C. Andaç	<b>Lecture</b> Antiviral Drugs E. N. Özdamar
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Antiviral agents and resistance G. Söyletir	<b>Lecture</b> Vaccines and antisera G. Söyletir	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Transplantation Immunology G. Yanikkaya Demirel/A. Aral/B. Aru	<b>Lecture</b> Vaccines and antisera G. Söyletir	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>16.00- 16.50</b>	<b>Lecture</b> Transplantation Immunology G. Yanikkaya Demirel/A. Aral/B. Aru	<b>Lecture</b> Pathology of Mycobacterial Infections A. Sav	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM**  
**WEEK IV / 30 Sep-4 Oct 2024**

	<b>Monday 30-Sep--2024</b>	<b>Tuesday 1-Oct--2024</b>	<b>Wednesday 2-Oct--2024</b>	<b>Thursday 3-Oct--2024</b>	<b>Friday 4-Oct--2024</b>			
09.00- 09.50	Independent Learning	ICP (Ear-Nose-Throat Examination) Z. Alkan / M. Kılıçoğlu	Independent Learning	Independent Learning	Independent Learning			
10.00- 10.50	Independent Learning	Group A IL	Group B IL	Group C Small Group Study SRPC	Group D ICP	Independent Learning	Independent Learning	<b>Lecture</b> Antiprotozoal Drugs E. N. Özdamar
11.00- 11.50	<b>Lecture</b> Hematostatic Drugs and Hematostatic Blood Products I A. C. Andaç					Independent Learning	<b>Lecture</b> Non/Hodgkin's Lymphoma I E. Hacıhasanoğlu	<b>Lecture</b> Antifungal Drugs E. N. Özdamar
12.00- 12.50	<b>Lecture</b> Hematostatic Drugs and Hematostatic Blood Products II A. C. Andaç	Independent Learning	<b>Lecture</b> Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen	<b>Lecture</b> Non/Hodgkin's Lymphoma II E. Hacıhasanoğlu	<b>Lecture</b> Antiseptics and Disinfectants E. N. Özdamar			
12.50- 14.00	LUNCH BREAK							
14.00- 14.50	ICP (Ear-Nose-Throat Examination) Z. Alkan / M. Kılıçoğlu	<b>Lecture</b> Blood Components and Transfusion Indications M. Sönmezoğlu	<b>Lecture</b> Occupational Health Hazards I M. Sönmezoğlu	<b>Lecture</b> Antianemic Drugs A. C. Andaç	<b>Lecture</b> Pathology of Viral Infections I A. Sav			
15.00- 15.50	Group A IL	Group B IL	Group C ICP	Group D Small Group Study SRPC	<b>Lecture</b> Blood Groups M. Sönmezoğlu	<b>Lecture</b> Occupational Health Hazards II M. Sönmezoğlu	<b>Lecture</b> Antihelminthic Drugs E. Genç	<b>Lecture</b> Pathology of Viral Infections II A. Sav
16.00- 16.50					<b>Lecture</b> Approach to the Pediatric Patient with Fever F. Coşkunol	<b>Lecture</b> Vaccines M. Sönmezoğlu	Independent Learning	Independent Learning
17.00-17.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning			

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM  
WEEK V / 7-11 Oct 2024**

	Monday 7-Oct--2024	Tuesday 8-Oct--2024	Wednesday 9-Oct--2024	Thursday 10-Oct--2024	Friday 11-Oct--2024			
09.00- 09.50	Independent Learning	Lecture Lenforeticular Infections I M. Sönmezoğlu	Independent Learning	Independent Learning	Independent Learning			
10.00- 10.50	Independent Learning	Lecture Lenforeticular Infections II M. Sönmezoğlu	ICP (Ear-Nose-Throat Examination) Z. Alkan / M. Kılıçoğlu		Independent Learning			
11.00- 11.50	Independent Learning	Lecture Systemic mycoses N. Çerikçioğlu	Group A ICP	Group B Small Group Study SRPC	Group C IL	Group D IL	Independent Learning	Independent Learning
12.00- 12.50	Lecture Approach to the Patients with platelet disorders F. Atalay	Lecture Systemic mycoses N. Çerikçioğlu					Independent Learning	Independent Learning
12.50 – 14.00	LUNCH BREAK							
14.00- 14.50	Lecture Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia E. Birtaş Ateşoğlu	Lecture Myeloproliferative Diseases E. Birtaş Ateşoğlu	Lecture Introduction to the Course E.Vatanoğlu Lutz	Lecture Transhumanisms and Ethics E.Vatanoğlu Lutz	Lecture Zoonotic Diseases G. Söyletir			
15.00- 15.50	Lecture Lymphoma E. Birtaş Ateşoğlu	Lecture Acute Leukemias E. Birtaş Ateşoğlu	Lecture Ethics of Publication E.Vatanoğlu Lutz	Lecture Ethics of the Future/Future of Ethics E.Vatanoğlu Lutz	Lecture Zoonotic Diseases G. Söyletir			
16.00- 16.50	Lecture Lymphoma E. Birtaş Ateşoğlu	Lecture Nutritional Anemias E. Birtaş Ateşoğlu	Lecture Physician-Patient Relationship E.Vatanoğlu Lutz	Lecture Bioethics E.Vatanoğlu Lutz	Independent Learning			
17.00-17.50	Lecture Phytotherapy I E. Güzelmeriç	Independent Learning	Lecture Confidentiality and Truthfulness E.Vatanoğlu Lutz	Lecture Responsible Biomedical Research E.Vatanoğlu Lutz	Independent Learning			

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM  
WEEK VI / 14-18 Oct 2024**

	<b>Monday 14-Oct--2024</b>	<b>Tuesday 15-Oct--2024</b>	<b>Wednesday 16-Oct--2024</b>	<b>Thursday 17-Oct--2024</b>	<b>Friday 18-Oct--2024</b>			
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Lecture</b> Plasma Cell Dyscrasias F. Atalay	<b>Lecture</b> Introduction to Clinical Oncology I B. B. Öven	<b>Lecture</b> Semiology-I M. Sönmezoğlu			
<b>10.00- 10.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Pathophysiology of Hematopoietic System Disorders I M. Kaçar	<b>Lecture</b> Hypercoagulability F. Atalay	<b>Lecture</b> Introduction to Clinical Oncology II B. B. Öven	<b>Lecture</b> Semiology-II M. Sönmezoğlu			
<b>11.00- 11.50</b>	<b>Lecture</b> Aminoglycosides E. Genç	<b>Lecture</b> Pathophysiology of Hematopoietic System Disorders II M. Kaçar	<b>Lecture</b> Approach to the Patient with Hemolytic anemia F. Atalay	<b>Lecture</b> Treatment Approaches of Cancer S. Çelik	<b>Lecture</b> <b>Anaerobic infections including tetanus</b> P.Çiragil			
<b>12.00- 12.50</b>	<b>Lecture</b> Sulfonamides, Chloramphenicol & Tetracyclines E. Genç	<b>Lecture</b> Pathophysiology of Hematopoietic System Disorders III M. Kaçar	<b>Lecture</b> Aplastic and Hypoplastic Anemias F. Atalay	<b>Lecture</b> Introduction to the Program of Family Medicine T. Sadıkoğlu	<b>Lecture</b> Approach to Fever in Primary Care T. Sadıkoğlu			
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>							
<b>14.00- 14.50</b>	<b>Lecture</b> Public Health and Communicable Diseases-I H. A. Taşyikan	<b>Lecture</b> Pharmacological Basis of Cancer Therapy I A. C. Andaç	<b>ICP</b> (Ear-Nose-Throat Examination) Z. Alkan / M. Kılıçoğlu		<b>Lecture</b> Antimalarial Drugs E. N. Özdamar	<b>Lecture</b> Prevention and Control of Communicable Diseases I H. Taşyikan		
<b>15.00- 15.50</b>	<b>Lecture</b> Public Health and Communicable Diseases-II H. A. Taşyikan	<b>Lecture</b> Introduction to Clinical Genetics A. Ç. Kuşkuç	<b>Group A</b> Small Group Study SRPC	<b>Group B</b> ICP	<b>Group C</b> IL	<b>Group D</b> IL	<b>Lecture</b> Quinolones E. N. Özdamar	<b>Lecture</b> Prevention and Control of Communicable Diseases II H. Taşyikan
<b>16.00- 16.50</b>	<b>Lecture</b> Phytotherapy II R. Konya Konuk	<b>Independent Learning</b>					<b>Independent Learning</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Lecture</b> Phytotherapy III R. Konya Konuk	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>			

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM**  
**WEEK VII / 21-25 Oct 2024**

	<b>Monday 21-Oct--2024</b>	<b>Tuesday 22-Oct--2024</b>	<b>Wednesday 23-Oct--2024</b>	<b>Thursday 24-Oct--2024</b>	<b>Friday 25-Oct--2024</b>
<b>09.00- 09.50</b>	<b>Independent learning</b>	<b>Independent learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>10.00- 10.50</b>	<b>Independent learning</b>	<b>Independent learning</b>	<b>Lecture Research Design Ç. Keleş</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>11.00- 11.50</b>	<b>Lecture Epidemiology of Communicable Diseases I H.A.Taşyikan</b>	<b>Lecture Planning Medical Studies I Ç. Keleş</b>	<b>Multidisciplinary Case Discussion Panel</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>12.00- 12.50</b>	<b>Lecture Epidemiology of Communicable Diseases II H.A.Taşyikan</b>	<b>Lecture Planning Medical Studies II Ç. Keleş</b>	<b>Multidisciplinary Case Discussion Panel</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture Pharmacological Basis of Cancer Therapy II A. C. Andaç</b>	<b>Lecture Investigation of a Disease Epidemic I H.A.Taşyikan</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture Immunodeficiencies G. Yanıkkaya Demirel/A. Aral/B. Aru</b>	<b>Lecture Investigation of a Disease Epidemic II H.A.Taşyikan</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>16.00- 16.50</b>	<b>Lecture Immunodeficiencies G. Yanıkkaya Demirel/A. Aral/B. Aru</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM  
WEEK VIII / 28 Oct-1 Nov 2024**

	<b>Monday 28-Oct--2024</b>	<b>Tuesday 29-Oct--2024</b>	<b>Wednesday 30-Oct--2024</b>	<b>Thursday 31-Oct--2024</b>	<b>Friday 01-Nov--2024</b>
09.00- 09.50	Independent Learning	NATIONAL HOLIDAY	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					Program Evaluation Session Committee I Coordination Committee Members
13.00 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	NATIONAL HOLIDAY	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

## COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

**DISTRIBUTION of LECTURE HOURS**  
**November 4, 2024 – December 20, 2024**  
**COMMITTEE DURATION: 7 WEEKS**

COURSES							
<b>MED 302</b>	<b>INTRODUCTION to CLINICAL SCIENCES</b>	<b>ABB.</b>	<b>THEO.</b>	<b>PRAC./LAB.</b>	<b>SMALL GROUP DISCUSSION</b>	<b>DISCUSSION</b>	<b>TOTAL</b>
	<b>DISCIPLINE/COMPONENTS</b>						
	PHARMACOLOGY	PC	25	0	0	0	<b>25</b>
	PATHOLOGY	PT	24	2Grx1H	0	0	<b>25</b>
	CHEST MEDICINE	CHM	18	0	0	0	<b>18</b>
	CARDIOLOGY	CRD	14	0	0	0	<b>14</b>
	PUBLIC HEALTH	PH	8	0	0	0	<b>8</b>
	PATHOPHYSIOLOGY	PP	7	0	0	0	<b>7</b>
	INFECTIOUS DISEASES	ID	5	0	0	0	<b>5</b>
	MEDICAL MICROBIOLOGY	MM	6	1H+4Grx2H	0	0	<b>9</b>
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	4	0	0	0	<b>4</b>
	EAR- NOSE -THROAT	ENT	4	0	0	0	<b>4</b>
	BIOSTATISTICS	BS	3	0	0	0	<b>3</b>
	THORACIC SURGERY	TS	3	0	0	0	<b>3</b>
	FAMILY MEDICINE	FM	3	0	0	0	<b>3</b>
	PEDIATRICS	PED	2	0	0	0	<b>2</b>
	MEDICAL GENETICS	MG	2	0	0	0	<b>2</b>
	EMERGENCY MEDICINE	EM	2	0	0	0	<b>2</b>
	IMMUNOLOGY	IMM	2	0	0	0	<b>2</b>
	RADIOLOGY	RAD	1	0	0	0	<b>1</b>
INTERDISCIPLINARY (CHM, CRD)	MCDP	0	0	0	2	<b>2</b>	
SCIENTIFIC RESEARCH and PROJECT COURSE- III	SRPC	0	0	4Grx8H	0	<b>8</b>	
<b>TOTAL</b>		<b>133</b>	<b>4</b>	<b>8</b>	<b>2</b>	<b>146</b>	
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III		4GrX12H			<b>12</b>
	<b>INDEPENDENT LEARNING HOURS</b>						<b>90</b>

### Coordination Committee

<b>HEAD</b>	Ferda Özkan, MD, Prof.
<b>SECRETARY</b>	Emine Nur Özdamar, MD, Assist. Prof.
<b>MEMBER</b>	Banu Musaffa Salepçi, MD, Prof.
<b>MEMBER</b>	Olçay Özveren, MD, Prof.
<b>MEMBER</b>	Zeynep Alkan, MD, Prof.



**COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS  
LECTURERS**

<b>MED 302 INTRODUCTION to CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof. Ahmet Cenk Andaç, PhD, Assist. Prof.
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof. Ezgi Hacıhasanoğlu, MD, Assist. Prof.
CHEST MEDICINE	Banu Musaffa Salepçi, MD, Prof. Seha Akduman, MD, Assist. Prof.
CARDIOLOGY	Olçay Özveren, MD, Prof. Tolga Aksu, MD, Prof. Ali Buturak, MD, Prof. Ayça Türer Cabbar, MD, Assoc. Prof. Songül Akkoyun, MD
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Prof.
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof.
MEDICAL MICROBIOLOGY	Güner Söyletir, MD, Prof. Aynur Eren Topkaya, MD, Prof. Pınar Çıragil, MD, Prof. Lab: Selvi Duman Bakırezer, PhD. Lab: Zehra Kipritçi, PhD.
EAR- NOSE -THROAT (ENT)	Zeynep Alkan, MD, Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
FAMILY MEDICINE	Tumay Sadıkoğlu, MD, Assist. Prof. Duygu Altıparmak, MD, Specialist, Instructor
PEDIATRICS	Özge Pamukçu Akay, MD, Assoc.Prof. Fulya Coşkunol, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assoc.Prof.
RADIOLOGY	Filiz Çelebi, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Yazıcıoğlu, MD, Assist. Prof.
BIostatISTICS	Çiğdem Keleş, PhD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
<b>OTHER COURSES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.
<b>MED 303 INTRODUCTION to CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Güldal İzbirak, MD, Prof. Tumay Sadıkoğlu, MD, Assist. Prof. Tuğhan Utku, MD, Prof. Özge Koner, MD, Prof. Banu Musaffa Salepçi, MD, Prof. Olçay Özveren, MD, Prof. Tolga Aksu, MD, Prof. Ali Buturak, MD, Prof. Serdar Özdemir, MD, Assist. Prof. Seha Akduman, MD, Assist. Prof. Duygu Altıparmak, MD, Specialist, Instructor Erdal Durmuş, MD

## **COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**

### **AIMS and LEARNING OBJECTIVES**

#### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in cardiovascular and respiratory clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to cardiovascular and respiratory clinical conditions, this committee aims to convey necessary knowledge on ethical problems, biostatistical knowledge required in the design of medical research and to convey necessary knowledge on genetic basis of clinical conditions, immune response and phytotherapy.

#### **LEARNING OBJECTIVES OF CARDIOVASCULAR SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency related to cardiovascular system, at the primary health care level; at the end of this committee, the student should be able to:

- C1. to recall knowledge on histology and physiology of cardiovascular system,
- C2. to define etiopathogenesis of clinical conditions related to cardiovascular system,
- C3. to explain epidemiology of clinical conditions related to cardiovascular system,
- C4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular system,
- C5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions related to cardiovascular system,
- C6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular system,
- C7. to convey knowledge on pharmacology of drugs that are effective on cardiovascular system or on clinical conditions involving cardiovascular system,
- C8. to define ethical problems encountered in health care service and utilization, and on principles of solutions,
- C9. to convey necessary knowledge on genetical basis of clinical conditions,
- C10. to explain principles of biostatistical analysis

#### **LEARNING OBJECTIVES OF RESPIRATORY SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency related to respiratory system, at the primary health care level; at the end of this committee, the student should be able to:

- R1. to recall knowledge on histology and physiology of respiratory system,
- R2. to define etiopathogenesis of clinical conditions related to respiratory system,
- R3. to explain epidemiology of clinical conditions related to respiratory system,
- R4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to respiratory system,
- R5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions related to respiratory system,
- R6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to respiratory system,
- R7. to convey knowledge on pharmacology of drugs that are effective on respiratory system, or on clinical conditions involving respiratory system,

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
C7,R7	PC	E. Genç	17	7	7	31
		E. N. Özdamar				
		A. C. Andaç				
C2,R2	PT	F. Özkan	16	7	7	30
		A. Sav				
R1-R6	CHM	B. Salepçi	12	5	5	22
		S. Akduman				
C1-C6	CRD	O. Özveren	10	4	4	18
		T. Aksu				
		A. Buturak				
		A. Tüter Cabbar				
S. Akkoyun						
C3,C4, R3	PH	H.A.Taşyikan	6	2	2	10
C2, R2	PP	M. Kaçar	5	2	2	9
C1-C6, R1-R6	ID	M. Sönmezoğlu	3	2	2	7
C2,C6,R2,R6	MM	Güner Söyletir	4	2	2	8
C8	BED	E. Vatanoğlu Lutz	3	1	1	5
R5	ENT	Z. Alkan	3	1	1	5
C10	BS	Ç. Keleş	2	1	1	4
R2, R5	TS	S. Ercan	2	1	1	4
C6, R6	FM	T. Sadıkoğlu	2	1	1	4
		D. Altıparmak				
C5, R5	PED	Ö. Pamukçu Akay	1	1	1	3
		F. Coşkunol				
C9	MG	A.Ç. Kuşkucu	1	1	1	3
C5	EM	M. Yazıcıoğlu	1	1	1	3
C5, R5	IMM	G.Y. Demirel	1	1	1	3
R5	RAD	F. Çelebi	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>40</b>	<b>40</b>	<b>170</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
R1-6	CHM	B. Salepçi	1	-	-	1
C2, R2	PT	A.Sav/F. Özkan	2	-	-	2
C1-6	CRD	A.T.Cabbar	2	-	-	2
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts:points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*40** out of 200 FE and ICE MCQs will be from Committee II (Each question is worth **0.5** pts).

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK I / 4 -8 Nov 2024**

	<b>Monday 4-Nov-2024</b>	<b>Tuesday 5-Nov-2024</b>	<b>Wednesday 6-Nov-2024</b>	<b>Thursday 7-Nov-2024</b>	<b>Friday 8-Nov-2024</b>			
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Electrocardiography I S. Akkoyun/ T. Aksu	Coronary Artery Disease I S. Akkoyun/ O. Özveren	<b>ICP-CSL</b> (Advanced Cardiac Life Support) T. Utku / Ö.Koner	<b>Lecture</b> Congestive Heart Failure F. Özkan			
<b>10.00- 10.50</b>	<b>Lecture</b> Hypertension Treatment Guidelines E. N. Özdamar	<b>Lecture</b> Electrocardiography II S. Akkoyun/ T. Aksu	<b>Lecture</b> Coronary Artery Disease II S. Akkoyun/ O. Özveren	<b>Group A</b> Small Group Study SRPC	<b>Group B ICP</b>	<b>Group C IL</b>	<b>Group D IL</b>	<b>Lecture</b> Congestive Heart Failure & Pericardium F. Özkan
<b>11.00- 11.50</b>	<b>Lecture</b> Anti-hypertensive Drugs I E. N. Özdamar	<b>Lecture</b> Hypertension A. Buturak	<b>Lecture</b> Acetylcholinesterase Inhibitors E. Genç					<b>Lecture</b> Principals of Statistical Analysis I Ç. Keleş
<b>12.00- 12.50</b>	<b>Lecture</b> Anti-hypertensive Drugs II E. N. Özdamar	<b>Lecture</b> Pericardial Diseases A. Buturak	<b>Lecture</b> Acetylcholine and Directly Acting Parasympathomimetic Drugs E. Genç	<b>Independent Learning</b>		<b>Lecture</b> Principals of Statistical Analysis II Ç. Keleş		
<b>12.50 - 14.00</b>	<b>LUNCH BREAK</b>							
<b>14.00- 14.50</b>	<b>Lecture</b> Pharmacology of ReninAngiotensin System E. N. Özdamar	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders I M. Kaçar	<b>Lecture</b> Bloodstream Invasion & Sepsis I M. Sönmezoğlu	<b>Lecture</b> Parasympatholitic Drugs E. Genç	<b>ICP-CSL</b> (Advanced Cardiac Life Support) T. Utku / Ö.Koner			
<b>15.00- 15.50</b>	<b>Lecture</b> Pharmacology Case Studies E. N. Özdamar	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders II M. Kaçar	<b>Lecture</b> Bloodstream Invasion & Sepsis II M. Sönmezoğlu	<b>Lecture</b> Sympathomimetic Drugs: Catecholamines & Noncatecholamines E. Genç	<b>Group A ICP</b>	<b>Group B</b> Small Group Study SRPC	<b>Group C IL</b>	<b>Group D IL</b>
<b>16.00- 16.50</b>	<b>Lecture</b> General Signs and Principal Symptoms in Cardiovascular System Diseases S. Akkoyun/ O. Özveren	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders III M. Kaçar	<b>Lecture</b> Cardiac Infections M. Sönmezoğlu	<b>Lecture</b> Microbiological approach to blood stream Infections G.Söyletir				
<b>17.00-17.50</b>	<b>Lecture</b> Examination of the Heart S. Akkoyun/ O. Özveren	<b>Lecture</b> Introduction to Autonomic System Pharmacology E. Genç	<b>Lecture</b> Cardiac Arrhythmias T. Aksu	<b>Lecture</b> Microbiological approach to blood stream Infections G.Söyletir	<b>Independent Learning</b>			

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK II / 11- 15 Nov 2024**

	<b>Monday 11-Nov-2024</b>	<b>Tuesday 12-Nov-2024</b>	<b>Wednesday 13-Nov-2024</b>	<b>Thursday 14-Nov-2024</b>	<b>Friday 15-Nov-2024</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Myocardium E. Hacıhasanoğlu	<b>Lecture</b> Grown-up Congenital Heart Disease A.T.Cabbar	<b>Lecture</b> Chronic Obstructive Pulmonary Diseases F. Özkan	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Ischemic Heart Disease I E. Hacıhasanoğlu	<b>Lecture</b> Adrenergic Neuron Blockers E. Genç	<b>Lecture</b> Asthma Bronchiale F. Özkan	<b>Lecture</b> Preparing to Analyse Data Ç. Keleş	<b>Independent Learning</b>
<b>11.00- 11.50</b>	<b>Lecture</b> Ischemic Heart Disease II E. Hacıhasanoğlu	<b>Lecture</b> Adrenergic Receptor Blockers E. Genç	<b>Lecture</b> Hypersensitivity reactions G. Yanıkkaya Demirel	<b>Lecture</b> Upper and Lower Respiratory System Infections I M. Sönmezoğlu	<b>Lecture</b> Approach to Patient with Chest Pain in Primary Care I T. Sadıkoğlu
<b>12.00- 12.50</b>	<b>Lecture</b> Congenital Heart Disease in Pediatrics Ö.Pamukçu Akay	<b>Independent Learning</b>	<b>Lecture</b> Hypersensitivity reactions G. Yanıkkaya Demirel	<b>Lecture</b> Upper and Lower Respiratory System Infections II M. Sönmezoğlu	<b>Lecture</b> Approach to Patient with Chest Pain in Primary Care II T. Sadıkoğlu
<b>12.50 - 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Valvular Heart Diseases A.T. Cabbar	<b>Lecture</b> History and Symptoms in Pulmonary Diseases S. Akduman	<b>Lecture</b> Diagnostic Methods in Pulmonary Medicine S. Akduman	<b>Independent Learning</b>	<b>Lecture</b> Pathophysiology of Respiratory System Disorders I M. Kaçar
<b>15.00- 15.50</b>	<b>Lecture</b> Infective Endocarditis and Acute Rheumatic Fever A.T. Cabbar	<b>Lecture</b> Physical Examination and Signs in Pulmonary Diseases S. Akduman	<b>Lecture</b> Clinical Application of Pulmonary Function Tests S. Akduman	<b>Independent Learning</b>	<b>Lecture</b> Pathophysiology of Respiratory System Disorders II M. Kaçar
<b>16.00- 16.50</b>	<b>Lecture</b> Congestive Heart Failure I A..T.Cabbar	<b>Lecture</b> Chronic Obstructive Pulmonary Disease S. Akduman	<b>Lecture</b> Bronchial Hyperreactivity and Asthma S. Akduman	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Lecture</b> Congestive Heart Failure II A..T.Cabbar	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK III / 18-22 Nov 2024**

	Monday 18-Nov-2024	Tuesday 19-Nov-2024	Wednesday 20-Nov-2024	Thursday 21-Nov-2024	Friday 22-Nov-2024
09.00- 09.50	<b>Lecture</b> Tracheobronchitis B. Salepçi	<b>Lecture</b> Pulmonary Tuberculosis B. Salepçi	<b>Lecture</b> Pathophysiology of Respiratory System Disorders III M. Kaçar	<b>Lecture</b> Rheumatic Heart Disease A. Sav	<b>ICP-CSL</b> (Advanced Cardiac Life Support) T. Utku / Ö.Koner
10.00- 10.50	<b>Lecture</b> Pneumoniae B. Salepçi	<b>Lecture</b> Pulmonary Embolism B. Salepçi	<b>Lecture</b> Pathophysiology of Respiratory System Disorders IV M. Kaçar	<b>Lecture</b> CVS Tumors A. Sav	
11.00- 11.50	<b>Lecture</b> Atherosclerosis & Hypertension I A. Sav	<b>Lecture</b> Special Pulmonary Problems B. Salepçi	<b>Lecture</b> Diseases of the Nose and Paranasal Sinuses Z. Alkan	<b>Lecture</b> Drugs Used in Cardiac Arrhythmias I A. C. Andaç	Independent Learning
12.00- 12.50	<b>Lecture</b> Atherosclerosis & Hypertension II A. Sav	<b>Lecture</b> Emergency Evaluation of Dyspnea S. Sarıkaya	<b>Lecture</b> Nasopharyngeal and Oropharyngeal Diseases Z. Alkan	<b>Lecture</b> Drugs Used in Cardiac Arrhythmias II A. C. Andaç	
12.50 – 14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>Lecture</b> Congenital Lung Anomalies & Atelectasis F. Özkan	<b>Lecture</b> Pulmonary Hypertension B. Salepçi	<b>ICP-CSL</b> (Approach to a Patient With Chest Pain) G. İzbırak/ T. Sadıkoğlu / S. Özdemir/ D. Altıparmak	<b>Lecture</b> Laryngeal and Voice Diseases Z. Alkan	<b>ICP-CSL</b> (Advanced Cardiac Life Support) T. Utku / Ö.Koner
15.00- 15.50	<b>Lecture</b> Pathology of Upper Respiratory Tract F. Özkan	<b>Lecture</b> Respiratory Failure B. Salepçi	Group A ICP Group C Small Group Study SRPC Group C IL Group D IL	<b>Lecture</b> Diseases of the Middle Ear and Eustachian Tube Z. Alkan	Group A IL Group B IL Group C Small Group Study SRPC Group D ICP
16.00- 16.50	Independent Learning	Independent Learning		<b>Lecture</b> Pulmonary Infections I E. Hacıhasanoğlu	
17.00-17.50	Independent Learning	Independent Learning	Independent Learning	<b>Lecture</b> Pulmonary Infections II E. Hacıhasanoğlu	Independent Learning

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK IV / 25-29 Nov 2024**

	<b>Monday 25-Nov-2024</b>				<b>Tuesday 26-Nov-2024</b>				<b>Wednesday 27-Nov-2024</b>				<b>Thursday 28-Nov-2024</b>				<b>Friday 29-Nov-2024</b>			
<b>09.00- 09.50</b>	<b>ICP-CSL</b> (Approach to a Patient With Chest Pain) G. İzbirak/ T. Sadıkoğlu / S. Özdemir/ D. Altıparmak				<b>Lecture</b> Pathology of Endocardium & Heart Valves I A. Sav				Lecture Microbiological approach to respiratory infections G. Söyletir				<b>Independent Learning</b>				<b>Lecture</b> Tobacco Control and Chronic Non-Communicable Diseases I H. A. Taşyikan			
<b>10.00- 10.50</b>	Group A Small Group Study SRPC	Group B ICP	Group C IL	Group D IL	<b>Lecture</b> Pathology of Endocardium & Heart Valves II A. Sav				Lecture Microbiological approach to respiratory infections G. Söyletir				<b>Lecture</b> Diuretic Agents I A.C. Andaç				<b>Lecture</b> Tobacco Control and Chronic Non-Communicable Diseases II H. A. Taşyikan			
<b>11.00- 11.50</b>					<b>Lecture</b> Tumors of the Respiratory System I A. Sav				Lecture Drugs Used in the Treatment of Dyslipidemias I E. N. Özdamar				<b>Lecture</b> Diuretic Agents II A.C. Andaç				<b>Lecture</b> Tobacco Control and Chronic Non-Communicable Diseases III H. A. Taşyikan			
<b>12.00- 12.50</b>	<b>Independent Learning</b>				<b>Lecture</b> Tumors of the Respiratory System II A. Sav				<b>Lecture</b> Drugs Used in the Treatment of Dyslipidemias II E. N. Özdamar				<b>Microbiology Laboratory Diagnostic Methods for respiratory infections-1</b> G. Söyletir, P. Çiragil. A.E Topkaya Z. Kipritçi, S.D Bakirezer				<b>Lecture</b> Pathology of Pleural and Mediastinal Diseases A. Sav			
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>																			
<b>14.00- 14.50</b>	<b>ICP-CSL</b> (Examination of Cardiovascular and Respiratory System) O. Özveren / T. Aksu / A. Buturak / B. Salepci / S. Akduman / E. Durmuş				<b>ICP-CSL</b> (Examination of Cardiovascular and Respiratory System) O. Özveren / T. Aksu / A. Buturak / B. Salepci / S. Akduman / E. Durmuş				<b>Lecture</b> Approach to respiratory symptoms in primary care D. Altıparmak				Group C				<b>Microbiology Laboratory Diagnostic Methods for respiratory infections-2</b> G. Söyletir, P. Çiragil. A.E Topkaya Z. Kipritçi, S.D Bakirezer Group D			
<b>15.00- 15.50</b>	Group C ICP	Group D Small Group Study SRPC	Group A IL	Group B IL	Group B Small Group Study SRPC	Group D ICP	Group A IL	Group B IL	<b>Lecture</b> Pediatric Advanced Life Support M. Yazıcıoğlu				Group D				Group C			
<b>16.00- 16.50</b>									<b>Independent Learning</b>				Group A				Group B			
<b>17.00-17.50</b>	<b>Independent Learning</b>				<b>Independent Learning</b>				<b>Independent Learning</b>				Group B				Group A			

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK V / 2 -6 Dec 2024**

	Monday 2-Dec-2024	Tuesday 3-Dec-2024	Wednesday 4-Dec-2024	Thursday 5-Dec-2024	Friday 6-Dec-2024
09.00-09.50	Independent Learning	Independent Learning	ICP-CSL (Examination of Cardiovascular and Respiratory System) O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş	ICP-CSL (Approach to a Patient With Chest Pain) G. İzbirak/ T. Sadıkoğlu / S. Özdemir/ D. Altıparmak	ICP-CSL History Taking G. İzbirak / T. Sadıkoğlu/ S. Özdemir / D. Altıparmak
10.00-10.50	<b>Lecture</b> Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan	<b>Lecture</b> Microbiological approach to cardiovascular diseases G. Söyletir	Group C IL	Group C ICP	Group A ICP
11.00-11.50	<b>Lecture</b> Surgical Disorders of Mediastinum and the Diaphragm S. Ercan	<b>Lecture</b> Microbiological approach to cardiovascular diseases G. Söyletir	Group D IL	Group D Small Group Study SRPC	Group C Small Group Study SRPC
12.00-12.50	<b>Lecture</b> Surgical Treatment of Pulmonary Diseases S. Ercan	<b>Lecture</b> Anticoagulant, Antiplatelet & Thrombolytic drugs E. N. Özdamar	Group B ICP	Group A IL	Group B IL
12.50-14.00	LUNCH BREAK				
14.00-14.50	Pathology Laboratory (Cardiovascular and Respiratory Systems) E. Hacıhasanoğlu	<b>Lecture</b> Treatment of Cough & Drugs Used in the Treatment of Common Cold E. N. Özdamar	Group A IL	ICP-CSL History Taking G. İzbirak / T. Sadıkoğlu/ S. Özdemir / D. Altıparmak	ICP-CSL (Examination of Cardiovascular and Respiratory System) O. Özveren / T. Aksu / A. Buturak / B. Salepçi / S. Akduman / E. Durmuş
15.00-15.50	Pathology Laboratory (Cardiovascular and Respiratory Systems) E. Hacıhasanoğlu	<b>Lecture</b> Drugs Used in Congestive Heart Disease I A.C. Andaç	Group B IL	Group C ICP	Group C IL
16.00-16.50	Independent Learning	<b>Lecture</b> Drugs Used in Congestive Heart Disease II A.C. Andaç	Group B Small Group Study SRPC	Group B Small Group Study SRPC	Group D IL
17.00-17.50	Independent Learning	<b>Lecture</b> Drugs Used in the Treatment of Angina Pectoris A.C. Andaç	Group A IL	Group D IL	Group B Small Group Study SRPC
			<b>Lecture</b> Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases H. A. Taşyikan	Independent Learning	Independent Learning



**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS**  
**WEEK VI / 9-13 Dec 2024**

	<b>Monday 9-Dec-2024</b>	<b>Tuesday 10-Dec-2024</b>	<b>Wednesday 11-Dec-2024</b>	<b>Thursday 12-Dec-2024</b>	<b>Friday 13-Dec-2024</b>	
<b>09.00- 09.50</b>	<b>Lecture</b> Bronchiectasis S. Akduman	<b>Lecture</b> Congenital Heart Disease I A. Sav	<b>Independent Learning</b>	<b>Lecture</b> Approach to the Pediatric Patient with Pneumonia F. Coşkunol	<b>ICP-CSL</b> History Taking G. İzbirak / T. Sadıkoğlu/ S. Özdemir / D. Altıparmak	
<b>10.00- 10.50</b>	<b>Lecture</b> Lung Cancer S. Akduman	<b>Lecture</b> Congenital Heart Disease II A. Sav	<b>Independent Learning</b>	<b>Lecture</b> Epidemiology and Prevention of Cardiovascular Diseases I H.A.Taşıykan	<b>Group B</b> ICP	
<b>11.00- 11.50</b>	<b>Lecture</b> Pleural Diseases S. Akduman	<b>Multidisciplinary Case Discussion Panel</b>	<b>Lecture</b> Inherited Respiratory System Disorders A. Ç. Kuşkucu	<b>Lecture</b> Epidemiology and Prevention of Cardiovascular Diseases II H.A.Taşıykan		<b>Group D</b> Small Group Study SRPC
<b>12.00- 12.50</b>	<b>Lecture</b> X-Ray Examination of the Lungs F. Çelebi	<b>Multidisciplinary Case Discussion Panel</b>	<b>Lecture</b> Inherited Cardiovascular Disorders A.Ç. Kuşkucu	<b>Lecture</b> Public Health and Chronic Non-Communicable Diseases H.A. Taşıykan	<b>Group A</b> IL	
<b>12.50- 14.00</b>	<b>LUNCH BREAK</b>					<b>Group C</b> IL
<b>14.00- 14.50</b>	<b>Lecture</b> Chronic Restrictive Pulmonary Diseases I A. Sav	<b>Lecture</b> Ethical Issues at the Beginning of Life E. Vatanoglu Lutz	<b>ICP-CSL</b> (Approach to a Patient With Chest Pain) G. İzbirak/ T. Sadıkoğlu / S. Özdemir/ D. Altıparmak	<b>Independent Learning</b>	<b>ICP-CSL</b> History Taking G. İzbirak / T. Sadıkoğlu/ S. Özdemir / D. Altıparmak	
<b>15.00- 15.50</b>	Chronic Restrictive Pulmonary Diseases II A. Sav	<b>Lecture</b> Ethical Issues in Paediatrics E. Vatanoglu Lutz	<b>Group C</b> Small Group Study	<b>Independent Learning</b>	<b>Group D</b> ICP	
<b>16.00- 16.50</b>	<b>Lecture</b> Interstitial Lung Diseases B. Salepçi	<b>Lecture</b> Ethics in Intensive Care E. Vatanoglu Lutz		<b>Group D</b> ICP		<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Lecture</b> Sleep Apnea Syndrome B. Salepçi	<b>Lecture</b> Ethics in Psychiatry E. Vatanoglu Lutz	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Group B</b> IL	
					<b>Group C</b> IL	

**COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS  
WEEK VII / 16-20 Dec 2024**

	<b>Monday 16-Dec-2024</b>	<b>Tuesday 17-Dec-2024</b>	<b>Wednesday 18-Dec-2024</b>	<b>Thursday 19-Dec-2024</b>	<b>Friday 20-Dec-2024</b>
09.00- 09.50	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
10.00- 10.50					<b>COMMITTEE EXAM</b>
11.00- 11.50					
12.00- 12.50					<b>Program Evaluation Session</b> Committee II Coordination Committee Members
13.00- 14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

**COMMITTEE III - GASTROINTESTINAL SYSTEM**

**DISTRIBUTION of LECTURE HOURS**

**December 23, 2024 – January 16, 2024**

**COMMITTEE DURATION: 4 WEEKS**

<b>COURSES</b>							
	<b>INTRODUCTION to CLINICAL SCIENCES</b>	<b>ABBR.</b>	<b>THEO.</b>	<b>PRAC./LAB.</b>	<b>SMALL GROUP DISCUSSION</b>	<b>DISCUSSION</b>	<b>TOTAL</b>
	<b>DISCIPLINE/COMPONENTS</b>						
<b>MED 302</b>	GASTROENTEROHEPATOLOGY	GE	24	0	0	0	<b>24</b>
	PATHOLOGY	PT	14	2GrX1H	0	0	<b>15</b>
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	10	0	0	0	<b>10</b>
	PHARMACOLOGY	PC	5	0	0	0	<b>5</b>
	INFECTIOUS DISEASES	ID	4	0	0	0	<b>4</b>
	MEDICAL MICROBIOLOGY	MM	2	0	0	0	<b>2</b>
	PUBLIC HEALTH	PH	3	0	0	0	<b>3</b>
	PHYTOTHERAPY	PHY	3	0	0	0	<b>3</b>
	BIOSTATISTICS	BS	3	0	0	0	<b>3</b>
	IMMUNOLOGY	IMM	2	0	0	0	<b>2</b>
	PATHOPHYSIOLOGY	PP	3	0	0	0	<b>3</b>
	FAMILY MEDICINE	FM	2	0	0	0	<b>2</b>
	MEDICAL GENETICS	MG	2	0	0	0	<b>2</b>
	EMERGENCY MEDICINE	EM	2	0	0	0	<b>2</b>
	RADIOLOGY	RAD	1	0	0	0	<b>1</b>
	PEDIATRICS	PED	1	0	0	0	<b>1</b>
	GENERAL SURGERY	GS	1	0	0	0	<b>1</b>
	INTERDISCIPLINARY (GE, PT)	MCDP	0	0	0	2	<b>2</b>
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC	0	0	4GrX2H	0	<b>2</b>
	<b>TOTAL</b>		<b>82</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>87</b>
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III		4GrX3H			<b>3</b>
	<b>INDEPENDENT LEARNING HOURS</b>						<b>54</b>

**Coordination Committee**

<b>HEAD</b>	Meltem Ergün, MD, Assoc. Prof.
<b>SECRETARY</b>	Didem Seven, PhD, Instructor
<b>MEMBER</b>	Ferda Özkan, MD, Prof.
<b>MEMBER</b>	Ezgi Hacıhasanoğlu, MD, Assist. Prof.
<b>MEMBER</b>	Başak Aru, PhD, Assist. Prof.

**COMMITTEE III - GASTROINTESTINAL SYSTEM  
LECTURERS**

<b>MED 302 INTRODUCTION to CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
GASTROENTEROHEPATOLOGY	Cengiz Pata, MD, Prof. Meltem Ergün, MD, Prof. M. Akif Öztürk, MD
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof. Ezgi Hacıhasanoğlu, MD, Assist. Prof
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof Ahmet Cenk Andaç, PhD, Assist. Prof
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Assist. Prof
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Prof.
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof.
MEDICAL MICROBIOLOGY	Güner Söyletir, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Prof.
PHYTOTHERAPY	Etil Güzelmeriç, PhD, Assoc. Prof. Rima Konya Konuk, PhD, Instructor
FAMILY MEDICINE	Tümay Sadıkoğlu, MD, Assist. Prof. Duygu Altıparmak, MD, Specialist, Instructor
BIOSTATISTICS	Çiğdem Keleş, PhD, Assist. Prof.
MEDICAL GENETICS	Didem Seven, PhD, Instructor
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Prof.
PEDIATRICS	Fulya Coşkunol, MD
GENERAL SURGERY	Alper Kurt, MD
RADIOLOGY	Ayşegül Görmez, MD, Assist. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
<b>OTHER COURSES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.

<b>MED 303 INTRODUCTION to CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Güldal İzbirak, MD, Prof. Tümay Sadıkoğlu, MD, Assist. Prof. Serdar Özdemir, MD, Assist. Prof. Duygu Altıparmak, MD, Specialist, Instructor Esra Bayar, MD Abidin Yusuf Kavurmacı, MD

## **COMMITTEE III - GASTROINTESTINAL SYSTEM**

### **AIMS and LEARNING OBJECTIVES**

#### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in gastrointestinal clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to gastrointestinal clinical conditions, this committee aims to convey necessary knowledge on ethical problems, biostatistical knowledge required in design of medical research and to convey necessary knowledge on genetic basis of clinical conditions, immune response and phytotherapy.

#### **LEARNING OBJECTIVES OF GASTROINTESTINAL SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency related to gastrointestinal system, at the primary health care level; at the end of this committee, the student should be able to:

- G1. to recall knowledge on histology and physiology of gastrointestinal system,
- G2. to define etiopathogenesis of clinical conditions related to gastrointestinal system,
- G3. to explain epidemiology of clinical conditions related to gastrointestinal system,
- G4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
- G5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions related to gastrointestinal system,
- G6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system,
- G7. to convey knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
- G8. to define ethical problems encountered in health care service and utilization, and on principles of solutions,
- G9. to convey necessary knowledge on genetical basis of clinical conditions,
- G10. to list principles of comparative biostatistical analysis of study groups,
- G11. to define basic knowledge on phytotherapy

**COMMITTEE III - GASTROINTESTINAL SYSTEM  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE III - GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
G1-G6	GE	C. Pata	27	7	7	41
		M. Ergün				
		M. A. Öztürk				
G2	PT	F. Özkan	16	4	4	24
		E. Hacıhasanoğlu				
G8	BED	E. Vatanoglu Lutz	11	2	2	15
G7	PC	E. Genç	6	1	1	8
		E. N. Özdamar				
		A. Cenk Andaç				
G1-G6	ID	M. Sönmezoğlu	5	1	1	7
G3,G6	MM	Güner Söyletir	2	1	1	4
G3, G4	PH	H.A.Taşıkan	3	1	1	5
G11	PHR (PHY)	E. Güzelmeriç	3	1	1	5
		R.Konya Konuk				
G10	BS	Ç. Keleş	3	1	1	5
G5	IMM	G. Y. Demirel	2	1	1	4
G2	PP	M. Kaçar	3	1	1	5
G6	FM	T. Sadıkoğlu	2	1	1	4
		D. Altıparmak				
G9	MG	D. Seven	2	1	1	4
G5	EM	S. Sarıkaya	2	1	1	4
G5	RAD	A. Görmez	1	0	0	1
G5	PED	F. Coşkunol	1	0	0	1
G5	GS	A.Kurt	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>24</b>	<b>24</b>	<b>138</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
G1-G6	GE	M. Ergün/ C. Pata /M. A. Öztürk	3	-	-	3
G2	PT	F. Özkan/ E. Hacıhasanoğlu	2	-	-	2
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts: Points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*24** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth **0.5** pts).

**COMMITTEE III - GASTROINTESTINAL SYSTEM**  
**WEEK I / 23-27 Dec 2024**

	<b>Monday 23-Dec-2024</b>	<b>Tuesday 24-Dec-2024</b>	<b>Wednesday 25-Dec-2024</b>	<b>Thursday 26-Dec-2024</b>	<b>Friday 27-Dec-2024</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Immunologic Tolerance and Autoimmunity G. Yanikkaya Demirel	<b>Independent Learning</b>	<b>Lecture</b> Radiology of Gastrointestinal System A. Görmez	<b>Lecture</b> Pathophysiology of Gastrointestinal Disorders I M. Kaçar	<b>Lecture</b> Pathology of Esophagus I F. Özkan
<b>10.00- 10.50</b>	<b>Lecture</b> Immunologic Tolerance and Autoimmunity G. Yanikkaya Demirel	<b>Lecture</b> Acute Gastroenteritis M. Sönmezoğlu	<b>Lecture</b> Abdominal Pain M. Ergün	<b>Lecture</b> Pathophysiology of Gastrointestinal Disorders II M. Kaçar	<b>Lecture</b> Pathology of Esophagus II F. Özkan
<b>11.00- 11.50</b>	<b>Lecture</b> Complex Diseases-Inherited Gastrointestinal System Disorders D. Seven	<b>Lecture</b> Hepatitis I M. Sönmezoğlu	<b>Lecture</b> Disease of the Bile Duct and Gall Bladder M. Ergün	<b>Lecture</b> Pathophysiology of Gastrointestinal Disorders III M. Kaçar	<b>Lecture</b> Comparing Groups-categorical Data Ç. Keleş
<b>12.00- 12.50</b>	<b>Lecture</b> Complex Diseases-Inherited Gastrointestinal System Disorders D. Seven	<b>Lecture</b> Semiology I M. A. Öztürk	<b>Lecture</b> Acute and Chronic Pancreatitis M. Ergün	<b>Lecture</b> Public Health and Nutrition I H. A. Taşyikan	<b>Lecture</b> Comparing Groups-countinous Data I Ç. Keleş
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Clinical Nutrition F. Coşkunol	<b>Lecture</b> Semiology II M. A. Öztürk	<b>Lecture</b> Functional GI Disorders & Irritable Bowel Disease C. Pata	<b>Lecture</b> Public Health and Nutrition II H. A. Taşyikan	<b>Lecture</b> Hepatitis II M. Sönmezoğlu
<b>15.00- 15.50</b>	<b>Lecture</b> Approach to the Patient with Abdominal Pain Regarding to Primary Care T. Sadikoğlu	<b>Lecture</b> Steatohepatitis M. A. Öztürk	<b>Lecture</b> Cirrhosis and Portal Hypertension C. Pata	<b>Lecture</b> Epidemiology, Prevention and Control of Obesity H. A. Taşyikan	<b>Lecture</b> Food Poisoning M. Sönmezoğlu
<b>16.00- 16.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Alcoholic Liver Disease M. A. Öztürk	<b>Lecture</b> Transplantation of liver A.Kurt	<b>Lecture</b> Phytotherapy-V R. Konya Konuk	<b>Lecture</b> Microbiological approach to gastrointestinal infections G.Söyletir
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Phytotherapy-IV E. Güzelmeriç	<b>Lecture</b> Mesenteric Ischemia S. Sarıkaya	<b>Lecture</b> Phytotherapy-VI R. Konya Konuk	<b>Lecture</b> Epidemiology and diagnosis of viral hepatitis G.Söyletir

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE III - GASTROINTESTINAL SYSTEM**

**WEEK II / 30 Dec 2024-3 Jan 2025**

	<b>Monday 30-Dec-2024</b>	<b>Tuesday 31-Dec-2024</b>	<b>Wednesday 1-Jan-2025</b>	<b>Thursday 2-Jan-2025</b>	<b>Friday 3-Jan-2025</b>		
<b>09.00- 09.50</b>	<b>Lecture</b> Jaundice M. Ergün	<b>Lecture</b> Pathology of Liver & Biliary System I E. Hacıhasanoğlu	<b>New Year's Day</b>	<b>Lecture</b> Pathology of Stomach I F. Özkan	<b>Lecture</b> Laxatives E. N. Özdamar		
<b>10.00- 10.50</b>	<b>Lecture</b> Tumors of Esophagus, Stomach and Small Intestine M. Ergün	<b>Lecture</b> Pathology of Liver & Biliary System II E. Hacıhasanoğlu		<b>Lecture</b> Pathology of Stomach II F. Özkan	<b>Lecture</b> Digestive & Antidiarrheal Drugs E. N. Özdamar		
<b>11.00- 11.50</b>	<b>Lecture</b> Acute Liver Failure M. Ergün	<b>Lecture</b> Pathology of Liver & Biliary System III E. Hacıhasanoğlu		<b>Pathology Laboratory (Gastrointestinal System) I System</b> E. Hacıhasanoğlu	<b>Group B</b>	<b>Group A II</b>	<b>Lecture</b> Wilson Disease and Hemochromatosis M. Ergün
<b>12.00- 12.50</b>	<b>Lecture</b> Autoimmune Hepatitis M. Ergün	<b>Lecture</b> Pathology of Liver & Biliary System IV E. Hacıhasanoğlu					<b>Pathology Laboratory (Gastrointestinal System) II System</b> E. Hacıhasanoğlu
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>						
<b>14.00- 14.50</b>	<b>Lecture</b> Antiemetic Agents A. C. Andaç	<b>Independent Learning</b>	<b>New Year's Day</b>	<b>Lecture</b> Comparing Groups-countinous Data II Ç. Keleş	<b>Lecture</b> Toxic Hepatitis M. Ergün		
<b>15.00- 15.50</b>	<b>Lecture</b> Oral Pathology F. Özkan			<b>Lecture</b> Gastritis and Helicobacter Pylori C. Pata	<b>Lecture</b> Tumors of the Bile Ducts and Pancreas M. Ergün		
<b>16.00- 16.50</b>	<b>Lecture</b> Agents used in the Treatment of Peptic Ulcer I E. Genç			<b>Lecture</b> Gastroesophageal Reflux (GE) and Esophageal Motility Disorder C. Pata	<b>Lecture</b> Malabsorption M. Ergün		
<b>17.00-17.50</b>	<b>Lecture</b> Agents used in the Treatment of Peptic Ulcer II E. Genç			<b>Lecture</b> Chronic /Viral Hepatitis C. Pata	<b>Lecture</b> Peptic Ulcer Disease M. Ergün		



**COMMITTEE III - GASTROINTESTINAL SYSTEM**  
**WEEK III / 6-10 Jan 2025**

	Monday 6-Jan-2025	Tuesday 7-Jan-2025	Wednesday 8-Jan-2025	Thursday 9 Jan-2025	Friday 10-Jan-2025						
09.00- 09.50	<b>Lecture</b> Pathology of Liver I E. Hacıhasanoğlu	<b>Lecture</b> Ethics of Dealing with Addiction E. Vatanoğlu Lutz	<b>ICP-CSL</b> Physical Examination of Gastrointestinal System <b>Group C ICP</b> E. Bayar/ A.Y. Kavurmacı	<b>ICP-CSL</b> Physical Examination of Gastrointestinal System <b>Group B ICP</b> E. Bayar/ A.Y. Kavurmacı	<b>ICP-CSL</b> Physical Examination of Gastrointestinal System) <b>Group D ICP</b> E. Bayar/ A.Y. Kavurmacı						
10.00- 10.50	<b>Lecture</b> Pathology of Liver II E. Hacıhasanoğlu	<b>Lecture</b> Ethics of Elective Interventions E. Vatanoğlu Lutz	Group D Small Group Study SRPC	Group B ICP	Group A Small Group Study SRPC	Group C IL	Group D IL	Group D ICP	Group C Small Group Study SRPC	Group A IL	Group B IL
11.00- 11.50	<b>Lecture</b> Pathology of Appendix & Peritoneum E. Hacıhasanoğlu	<b>Lecture</b> The Ethics of Testing and Screening E. Vatanoğlu Lutz									
12.00- 12.50	<b>Lecture</b> Palliative Care Ethics E. Vatanoğlu Lutz	<b>Lecture</b> The Ethics of Dealing with Infectious Diseases E. Vatanoğlu Lutz	<b>Independent Learning</b>		<b>Lecture</b> Approach to gastrointestinal symptoms in primary care D. Altıparmak	<b>Independent Learning</b>					
12.50 – 14.00	<b>LUNCH BREAK</b>										
14.00- 14.50	<b>Lecture</b> Medical Ethical Decision-Making E. Vatanoğlu Lutz	<b>Lecture</b> Ethical Issues at the End of Life E. Vatanoğlu Lutz	<b>Lecture</b> Pathology of Intestinal Diseases I F. Özkan		<b>Lecture</b> Inflammatory Bowel Disease M. Ergün		<b>INTRODUCTION TO ELECTIVE COURSES (ONLINE)</b>				
15.00- 15.50	<b>Lecture</b> Ethics and the Law E. Vatanoğlu Lutz	<b>ICP-CSL</b> Physical Examination of Gastrointestinal System <b>Group A ICP</b> E. Bayar/ A.Y. Kavurmacı		<b>Lecture</b> Pathology of Intestinal Diseases II F. Özkan		<b>Lecture</b> Premalignant Lesion of the Colon M. Ergün		<b>INTRODUCTION TO ELECTIVE COURSES (ONLINE)</b>			
16.00- 16.50	<b>Lecture</b> Public Health Ethics E. Vatanoğlu Lutz	Group A ICP	Group B Small Group Study SRPC	Group C IL	Group D IL	<b>Lecture</b> Clinical Approach to the Patient with Acute Abdominal Pain S. Sarıkaya		<b>Multidisciplinary Case Discussion Panel</b>		<b>Independent Learning</b>	
17.00-17.50	<b>Lecture</b> The Ethics of Patents on Life E. Vatanoğlu Lutz					<b>Independent Learning</b>		<b>Multidisciplinary Case Discussion Panel</b>		<b>Independent Learning</b>	

**COMMITTEE III - GASTROINTESTINAL SYSTEM  
WEEK IV / 13-17 Jan 2025**

	<b>Monday 13-Jan-2025</b>	<b>Tuesday 14-Jan-2025</b>	<b>Wednesday 15-Jan-2025</b>	<b>Thursday 16-Jan-2025</b>	<b>Friday 17-Jan-2025</b>
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>10.00- 10.50</b>				<b>COMMITTEE EXAM</b>	
<b>11.00- 11.50</b>					
<b>12.00- 12.50</b>				<b>Program Evaluation Session Committee III Coordination Committee Members</b>	
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>15.00 -15.50</b>					
<b>16.00 - 16.50</b>					
<b>17.00 - 17.50</b>					

**MIDTERM BREAK  
20 – 31 JANUARY 2025**

## COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

### DISTRIBUTION of LECTURE HOURS

February 3, 2025 – March 21, 2025

COMMITTEE DURATION: 7 WEEKS

COURSES							
	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC./LAB.	SMALL GROUP DISCUSSION	DISCUSSION	TOTAL
	DISCIPLINE/COMPONENTS						
<b>MED 302</b>	PATHOLOGY	PT	32	2GrX1H	0	0	33
	OBST & GYNEC	OBS-GYN	17	0	0	0	17
	ENDOCRINOLOGY	END	13	0	0	0	13
	NEPHROLOGY	NE	15	0	0	0	15
	PHARMACOLOGY	PC	14	0	0	0	14
	INFECTIOUS DISEASES	ID	5	0	0	0	5
	MEDICAL MICROBIOLOGY	MM	2	1H+4GrX2H	0	0	5
	PATHOPHYSIOLOGY	PP	7	0	0	0	7
	MEDICAL GENETICS	MG	6	0	0	0	6
	PEDIATRICS	PED	3	0	0	0	3
	UROLOGY	URO	6	0	0	0	6
	FAMILY MEDICINE	FM	5	0	0	0	5
	PUBLIC HEALTH	PH	4	0	0	0	4
	BIOSTATISTICS	BS	3	0	0	0	3
	PEDIATRIC ENDOCRINOLOGY	PE	3	0	0	0	3
	IMMUNOLOGY	IM	2	0	0	0	2
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	2	0	0	0	2
	PHYTOTHERAPY	PHR	2	0	0	0	2
	RADIOLOGY	RAD	2	0	0	0	2
	EMERGENCY MEDICINE	EM	1	0	0	0	1
	PEDIATRIC SURGERY	PED-S	1	0	0	0	1
	GENERAL SURGERY	GS	1	0	0	0	1
INTERDISCIPLINARY (NE, END, URO, OBS-GYN, PT)	MCDP	0	0	0	0	2	
SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC	2	0	4GrX4H	0	6	
	<b>TOTAL</b>		148	4	4	2	158
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III		4GrX9H			9
	<b>INDEPENDENT LEARNING HOURS</b>						<b>84</b>

#### Coordination Committee

<b>HEAD</b>	Ruket Attar, MD, Prof.
<b>SECRETARY</b>	Cenk Andaç, PhD, Assist. Prof.
<b>MEMBER</b>	Murat Aydın Sav, MD, Prof.
<b>MEMBER</b>	Gülçin Kantarcı, MD, Prof.
<b>MEMBER</b>	Özlem Haliloğlu, MD, Assoc. Prof.

## COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	LECTURERS
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof. Ezgi Hacıhasanoğlu, MD, Assist. Prof.
OBSTETRICS and GYNECOLOGY	Orhan Ünal, MD, Prof. Rukset Attar, MD, Prof. Erkut Attar, MD Prof. Melis Gökçe Koçer Yazıcı, MD, Assist. Prof. Tanju Demirören, MD, Assist. Prof.
ENDOCRINOLOGY	Fahrettin Keleştemur, MD, Prof. Özlem Haliloğlu, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD Prof.
MEDICAL MICROBIOLOGY	Aynur Eren Topkaya, MD, Prof. Güner Söyletir, MD, Prof. Pınar Çırağil, MD, Prof. Lab: Selvi Duman Bakırezer, PhD. Lab: Zehra Kipritçi, PhD.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Prof.
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Assist. Prof.
FAMILY MEDICINE	Tumay Sadıkoğlu, MD, Assist. Prof. Duygu Altıparmak, MD, Specialist, Instructor
PEDIATRICS	Mustafa Berber, MD, Assist. Prof. Coşkun Saf, MD, Assist. Prof. Fulya Coşkunol, MD
PEDIATRIC ENDOCRINOLOGY	Elif Sağsak, MD, Assoc. Prof.
BIostatISTICS	Çiğdem Keleş, PhD, Assist. Prof.
RADIOLOGY	Ayşegül Görmez, MD, Assist. Prof.
PHYTOTHERAPY	Etil Güzelmeriç, PhD, Assoc. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD, Prof. Abdullah Özkök, MD, Prof
UROLOGY	Ali Cihangir Çetinel, MD.
PEDIATRIC SURGERY	Şafak Karaçay, MD, Prof.
GENERAL SURGERY	Alper Kurt, MD
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
OTHER COURSES	
DISCIPLINE	LECTURERS
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.
MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	LECTURERS
CLINICAL SKILLS LAB	Rukset Attar, MD, Prof Bilge Kağan Aysal, MD, Assoc. Prof. Mert Yeşiladalı, MD, Assist. Prof. Melis Gökçe Koçer Yazıcı, MD, Assist. Prof. Mustafa Berber, MD, Assist. Prof. Mert Ersan, MD Emre Özer, MD

## **COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS AIMS and LEARNING OBJECTIVES**

### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in endocrine, reproductive and urinary clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to endocrine, reproductive and urinary clinical conditions, this committee aims to convey necessary knowledge on ethical problems, biostatistical knowledge required in the design of medical research and to convey necessary knowledge on genetic basis of clinical conditions, immune response and phytotherapy.

### **LEARNING OBJECTIVES OF ENDOCRINE and REPRODUCTIVE SYSTEMS**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency, at the primary health care level; at the end of this committee, the student should be able to:

- E.1. to recall knowledge on anatomy, histology, and physiology of endocrine and reproductive systems,
- E.2. to define etiopathogenesis of clinical conditions related to endocrine and reproductive systems,
- E.3. to explain epidemiology of clinical conditions related to endocrine and reproductive systems,
- E.4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
- E.5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs, and findings in clinical conditions related to endocrine and reproductive systems,
- E.6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems,
- E.7. to convey knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
- E.8. to convey necessary knowledge on genetic basis of clinical conditions related to endocrine and reproductive systems,
- E.9. to define biostatistical analysis of association between variables
- E.10. to convey knowledge on phytotherapeutic agents that are effective on endocrine, reproductive, and urinary systems or on clinical conditions involving endocrine, reproductive, and urinary systems,
- E.11. to define ethical problems encountered in health care service and utilization, and on principles of solutions,

## **LEARNING OBJECTIVES OF URINARY SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency, at the primary health care level; at the end of this committee, the student should be able to:

U.1. to recall knowledge on anatomy, histology, and physiology of urinary system,

U.2. to define etiopathogenesis of clinical conditions related to urinary system,

U.3. to explain epidemiology of clinical conditions related to urinary system,

U.4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,

U.5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs, and findings in clinical conditions related to urinary system,

U.6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system,

U.7. to convey knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,

U.8. to convey necessary knowledge on genetic basis of clinical conditions related to urinary system,

**COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
E.2, U.2	PT	F. Özkan	20	9	9	38
		A. Sav				
		E. Hacıhasanoğlu				
E.1 – E.6	OBS-GYN	O. Ünal	10	5	5	20
		R. Attar				
		M.G.Koçer Yazıcı				
		T. Demirören				
		E. Attar				
E.1 – E.6	END	F. Keleştemur	8	3	3	14
		Ö. Haliloğlu				
U.1 – U.6	NE	G. Kantarcı	9	4	4	17
		A.Özkök				
E.7, U.7	PC	E. Genç	9	4	4	17
		E. N. Özdamar				
E.1 – E.6, U.1 – U.6	ID	M. Sönmezoğlu	3	2	2	7
E2, E6,U2, U6	MM	Güner Söyletir	1	1	1	3
E.5, U.5	PP	M. Kaçar	4	2	2	8
E.8, U.8	MG	A. Ç. Kuşkucu	4	2	2	8
E.1 – E.6, U.1 – U.6	PED	M. Berber	2	1	1	4
		C. Saf				
		F. Coşkunol				
E.1 – E.6	PED END	E. Sağsak	2	1	1	4
U.1 – U.6	URO	A. C. Çetinel	4	2	2	8
E.6, U.6	FM	T. Sadikoğlu	3	2	2	7
		D. Altıparmak				
E.3, E.4, U.3, U.4	PH	H.A. Taşyikan	2	1	1	4
E.9	BS	Ç. Keleş	2	1	1	4
E.5	IMM	G. Y. Demirel	1	1	1	3
E.11	BED	E. Vatanoğlu Lutz	1	1	1	3
E.10	PHR (PHY)	E. Güzelmeriç	1	1	1	3
E.5, U.5	RAD	A. Görmez	1	1	1	3
E.5, U.5	EM	S. Sarıkaya	1	0	0	1
E.5, U.5	PED-S	Ş. Karaçay	1	0	0	1
E.5, U.5	GS	A.Kurt	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>44</b>	<b>44</b>	<b>178</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
E.1 – E.6	END	Ö. Haliloğlu	1	-	-	1
E.1 – E.6	OBS-GYN	M. Yeşiladalı	1	-	-	1
U.1 – U.6	NE	A. Özkök	1	-	-	1
U.1 – U.6	URO	A. C. Çetinel	1	-	-	1
E.2, U.2	PT	E. Hacıhasanoğlu	1	-	-	1
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 point; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam; **pts:** Points

**\*\*44** out of 200 FE and ICE MCQs will be from Committee IV (Each question is worth **0.5** pts).



**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEM**  
**WEEK 1 / 3 – 7 Feb 2025**

	<b>Monday 3-Feb-2025</b>	<b>Tuesday 4-Feb-2025</b>	<b>Wednesday 5-Feb-2025</b>	<b>Thursday 6-Feb-2025</b>				<b>Friday 7-Feb-2025</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Introduction to Endocrinology F. Keleştemur	<b>Lecture</b> Pathology of Adrenal Gland I A. Sav	<b>Lecture</b> Pathophysiology of Endocrine System Diseases I M. Kaçar	<b>ICP-CSL</b> Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining R. Attar/ M. Yeşiladalı / M.G.K. Yazıcı				<b>Independent Learning</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Introduction to Diabetes Mellitus Ö. Haliloğlu	<b>Lecture</b> Pathology of Adrenal Gland II A. Sav	<b>Lecture</b> Research Project Components-II SRPC A. Yaba Uçar	<b>Group A ICP</b>	<b>Group B Small Group Study SRPC</b>	<b>Group C IL</b>	<b>Group D IL</b>	<b>Lecture</b> Introduction to Endocrine Pharmacology E. Genç
<b>11.00- 11.50</b>	<b>Lecture</b> Clinical and Laboratory Findings of Diabetes Mellitus Ö. Haliloğlu	<b>Lecture</b> Upper and Lower Urinary Tract Infections I M. Sönmezoğlu	<b>Lecture</b> How to Write a Research Project?-II SRPC A. Yaba Uçar					<b>Lecture</b> Thyroid and Antithyroid Drugs I E. Genç
<b>12.00- 12.50</b>	<b>Lecture</b> Obesity Ö. Haliloğlu	<b>Lecture</b> Upper and Lower Urinary Tract Infections II M. Sönmezoğlu	<b>Lecture</b> Hypertensive Disorders in Pregnancy S. Sarıkaya	<b>Independent Learning</b>				<b>Lecture</b> Thyroid and Antithyroid Drugs II E. Genç
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>							
<b>14.00- 14.50</b>	<b>Lecture</b> Pathology of Endocrine System: Introduction A. Sav	<b>Lecture</b> Calcium Metabolism Ö. Haliloğlu	<b>Lecture</b> Prenatal Genetic Diagnosis A. Ç. Kuşkuçcu	<b>Lecture</b> Normal Pubertal Development E. Sağsak				<b>Lecture</b> Hypoglycemia F. Keleştemur
<b>15.00- 15.50</b>	<b>Lecture</b> Pathology of Pituitary Gland I A. Sav	<b>Lecture</b> Physical Examination of Newborn Patient M. Berber	<b>Lecture</b> Genetic Counseling A. Ç. Kuşkuçcu	<b>Lecture</b> Congenital Adrenal Hyperplasia E. Sağsak				<b>Lecture</b> Hypercalcemic Diseases Ö. Haliloğlu
<b>16.00- 16.50</b>	<b>Lecture</b> Pathology of Pituitary Gland II A. Sav	<b>Lecture</b> Physical Examination of Child Patient F. Coşkunol	<b>Lecture</b> Pathology of Pancreas A. Sav	<b>Lecture</b> Pubertal Disorders E. Sağsak				<b>Lecture</b> Pathology of Thyroid & Parathyroid I A. Sav
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Imaging of Thyroid Glands A. Görmez	<b>Lecture</b> Pathology of Pancreas A. Sav	<b>Independent Learning</b>				<b>Lecture</b> Pathology of Thyroid & Parathyroid II A. Sav

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**  
**WEEK II / 10 – 14 Feb 2025**

	<b>Monday 10-Feb-2025</b>	<b>Tuesday 11-Feb-2025</b>	<b>Wednesday 12-Feb-2025</b>	<b>Thursday 13-Feb-2025</b>				<b>Friday 14-Feb-2025</b>	
<b>09.00- 09.50</b>	<b>Lecture</b> Puerperal Infections T. Demirören	<b>Lecture</b> Fluid, Electrolyte I G. Kantarcı	<b>Lecture</b> Epidemiology, Prevention and Control of Type II Diabetes Mellitus H. A. Taşyikan	<b>ICP-CSL</b> Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining R. Attar/ M. Yeşiladalı / M.G.K. Yazıcı				<b>Independent Learning</b>	
<b>10.00- 10.50</b>	<b>Lecture</b> Normal and Abnormal Labor T. Demirören	<b>Lecture</b> Fluid, Electrolyte II G. Kantarcı	<b>Lecture</b> Reproductive, Maternal and Child Health II H. A. Taşyikan	<b>Group A</b> Small Group Study SRPC	<b>Group B</b> ICP	<b>Group C</b> IL	<b>Group D</b> IL	<b>Lecture</b> Conditions Affecting Vulva & Vagina O. Ünal	
<b>11.00- 11.50</b>	<b>Lecture</b> Insulin and Oral Antidiabetic Drugs I E. Genç	<b>Lecture</b> Hyperfunctioning Disorders of Anterior Pituitary Gland F. Keleştemur	<b>Lecture</b> The Gynecological History and Examination M.G. Koçer Yazıcı					<b>Lecture</b> Conditions Affecting Vulva & Vagina O. Ünal	
<b>12.00- 12.50</b>	<b>Lecture</b> Insulin and Oral Antidiabetic Drugs II E. Genç	<b>Lecture</b> Disorders of Posterior Pituitary Gland F. Keleştemur	<b>Lecture</b> Endometriosis & Adenomyosis E. Attar	<b>Lecture</b> Congenital Anomalies of The Urinary System Ş. Karaçay				<b>Lecture</b> Menopause M. G. Koçer Yazıcı	
<b>12.50-14.00</b>	<b>LUNCH BREAK</b>								
<b>14.00- 14.50</b>	<b>Lecture</b> Pathology of Vulva & Vagina F. Özkan	<b>Lecture</b> Neuroendocrine tumors Ö. Haliloğlu	<b>Lecture</b> Adrenocortical Hormones and Drugs I E. Genç	<b>Lecture</b> Approach to breast diseases in primary care D. Altıparmak				<b>ELECTIVE WEEK I</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Pathology of Treponemal Infections F. Özkan	<b>Lecture</b> Thyroid Function Tests and Thyroid Disorders Ö. Haliloğlu	<b>Lecture</b> Adrenocortical Hormones and Drugs II E. Genç	<b>Lecture</b> Delivery of Family Planning Services I D. Altıparmak					
<b>16.00- 16.50</b>	<b>Lecture</b> Pathophysiology of Endocrine System Diseases II M. Kaçar	<b>Lecture</b> Microbiological approach to urinary tracts infections G.Söyletir	<b>Lecture</b> Antenatal Care T. Demirören	<b>Lecture</b> Delivery of Family Planning Services II D. Altıparmak				<b>Independent Learning</b>	<b>ELECTIVE WEEK I</b>
<b>17.00-17.50</b>	<b>Lecture</b> Pathophysiology of Endocrine System Diseases III M. Kaçar	<b>Independent Learning</b>	<b>Lecture</b> Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD) T. Demirören	<b>Lecture</b> Imaging of Urinary System A.Görmez					

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**  
**WEEK III / 17 – 21 Feb 2025**

	<b>Monday 17-Feb-2025</b>	<b>Tuesday 18-Feb-2025</b>	<b>Wednesday 19-Feb-2025</b>	<b>Thursday 20-Feb-2025</b>	<b>Friday 21-Feb-2025</b>
<b>09.00-09.50</b>	<b>Lecture</b> Pathology of Breast I F. Özkan	<b>Independent learning</b>	<b>Lecture</b> Immunology of Reproduction G. Yanikkaya Demirel	<b>ICP-CSL</b> Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP R. Attar/ M. Yeşiladalı / M.G.K. Yazıcı	<b>ICP-CSL</b> Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP R. Attar/ M. Yeşiladalı / M.G.K. Yazıcı
<b>10.00-10.50</b>	<b>Lecture</b> Pathology of Breast II F. Özkan	<b>Lecture</b> Congenital Infections and Sexually Transmitted Diseases, Genital Infections I M. Sönmezoğlu	<b>Lecture</b> Immunology of Reproduction G. Yanikkaya Demirel	<b>Group A IL</b> <b>Group B IL</b> <b>Group C ICP</b> <b>Group D Small Group Study SRPC</b>	<b>Group A IL</b> <b>Group B IL</b> <b>Group C Small Group Study SRPC</b> <b>Group D ICP</b>
<b>11.00-11.50</b>	<b>Lecture</b> Pathophysiology of Reproductive System Diseases I M. Kaçar	<b>Lecture</b> Congenital Infections and Sexually Transmitted Diseases, Genital Infections II M. Sönmezoğlu	<b>Lecture</b> Hypocalcemic Diseases Ö. Haliloğlu		
<b>12.00-12.50</b>	<b>Lecture</b> Pathophysiology of Reproductive System Diseases II M. Kaçar	<b>Lecture</b> Congenital Infections and Sexually Transmitted Diseases, Genital Infections III M. Sönmezoğlu	<b>Lecture</b> Adrenal Disorders F. Keleştemur	<b>Independent learning</b>	<b>Independent learning</b>
<b>12.50-14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00-14.50</b>	<b>Lecture</b> Fertility Control E. Attar	<b>Lecture</b> Microbiological approach to genital infections G. Söyletir	<b>Lecture</b> Pathology of Urinary System Tumors E. Hacıhasanoğlu	<b>Lecture</b> Reproductive, Maternal and Child Health II H. A. Taşyikan	<b>ELECTIVE WEEK II</b> <b>Independent Learning</b>
<b>15.00-15.50</b>	<b>Lecture</b> Infertility E. Attar	<b>Lecture</b> Acute Kidney Injury-I G. Kantarcı	<b>Lecture</b> Congenital Anomalies of Urinary System E. Hacıhasanoğlu	<b>Lecture</b> Reproductive, Maternal and Child Health II H. A. Taşyikan	
<b>16.00-16.50</b>	<b>Lecture</b> Normal and Abnormal Sexual Development & Puberty R. Attar	<b>Lecture</b> Acute Kidney Injury-II G. Kantarcı	<b>Independent learning</b>	<b>Lecture</b> Agents Effecting Bone Mineral Homeostasis I E. Genç	<b>Independent Learning</b> <b>ELECTIVE WEEK II</b>
<b>17.00-17.50</b>	<b>Lecture</b> The Menstrual Cycle and Disorders of the Menstrual Cycle R. Attar	<b>Lecture</b> Clinical Study of Renal Functions and Urinary Findings G. Kantarcı	<b>Independent learning</b>	<b>Lecture</b> Agents Effecting Bone Mineral Homeostasis II E. Genç	

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**

**WEEK IV / 24 – 28 Feb 2025**

	<b>Monday 24-Feb-2025</b>	<b>Tuesday 25-Feb-2025</b>	<b>Wednesday 26-Feb-2025</b>	<b>Thursday 27-Feb-2025</b>	<b>Friday 28-Feb-2025</b>		
<b>09.00- 09.50</b>	<b>Lecture</b> Pathology of Glomerular Diseases I <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Pathology of Ovary I <i>F. Özkan</i>	<b>Lecture</b> Benign Diseases of the Uterus and the Cervix <i>R. Attar</i>	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Cervix Uteri I <i>F. Özkan</i>		
<b>10.00- 10.50</b>	<b>Lecture</b> Pathology of Glomerular Diseases II <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Pathology of Ovary II <i>F. Özkan</i>	<b>Lecture</b> Benign Diseases of the Ovary <i>R. Attar</i>	<b>Program Improvement Session</b>	<b>Lecture</b> Pathology of Cervix Uteri II <i>F. Özkan</i>		
<b>11.00- 11.50</b>	<b>Lecture</b> Pathology of Glomerular Diseases III <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Pathology of Tubulointerstitial Disease I <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Nephritic Syndrome <i>G. Kantarcı</i>	<b>Lecture</b> Malign Diseases of the Uterus and the Cervix <i>O. Ünal</i>	<b>Lecture</b> Chromosomal Disorders I <i>A. Ç. Kuşkucu</i>		
<b>12.00- 12.50</b>	<b>Lecture</b> Androgens & Anabolic Steroids <i>E. Genç</i>	<b>Lecture</b> Pathology of Tubulointerstitial Disease II <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Nephrotic Syndrome <i>G. Kantarcı</i>	<b>Lecture</b> Malign Diseases of the Ovary <i>O. Ünal</i>	<b>Lecture</b> Chromosomal Disorders II (Sex Chromosomes and their Abnormalities) <i>A. Ç. Kuşkucu</i>		
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>						
<b>14.00- 14.50</b>	<b>Lecture</b> Reproductive Ethics <i>E. Vatanoglu Lutz</i>	<b>ICP-CSL</b> (Clinical Breast Examination) <i>B.K. Aysal/M. Ersan/ E.Özer</i>		<b>Lecture</b> Relation Between Two Variables I <i>Ç. Keleş</i>	<b>ELECTIVE WEEK III</b>	<b>Independent Learning</b>	
<b>15.00- 15.50</b>	<b>Lecture</b> Gene Ethics <i>E. Vatanoglu Lutz</i>	<b>Group A IIL</b>	<b>Group B IIL</b>	<b>Lecture</b> Relation Between Two Variables II <i>Ç. Keleş</i>			<b>Lecture</b> Pathology of Uterus II <i>F. Özkan</i>
<b>16.00- 16.50</b>	<b>Lecture</b> Renovascular Pathology <i>E. Hacıhasanoğlu</i>	<b>Group C Small Group Study</b>	<b>Group D ICP</b>	<b>Lecture</b> Pathophysiology of Urinary System Diseases I <i>M. Kaçar</i>	<b>Lecture</b> The Kidney Systemic Disease and Inherited Disorders <i>A. Özkök</i>	<b>Independent Learning</b>	<b>ELECTIVE WEEK III</b>
<b>17.00-17.50</b>	<b>Lecture</b> Renal Cystic Disease <i>E. Hacıhasanoğlu</i>			<b>Independent Learning</b>	<b>Lecture</b> Pathophysiology of Urinary System Diseases II <i>M. Kaçar</i>		

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**

**WEEK V / 3 – 7 Mar 2025**

	<b>Monday 3-Mar-2025</b>	<b>Tuesday 4-Mar-2025</b>	<b>Wednesday 5-Mar-2025</b>	<b>Thursday 6-Mar-2025</b>	<b>Friday 7-Mar-2025</b>					
<b>09.00- 09.50</b>	<b>Lecture</b> Benign Prostatic Hyperplasia-I A.Ç. Çetinel	<b>Lecture</b> Urologic Oncology I A.Ç. Çetinel	<b>Lecture</b> Chronic Kidney Disease A.Özkök	<b>Independent Learning</b>	<b>Microbiology Laboratory</b> Diagnostic Tests for Urinary and genital Specimens-2 G. Söyletir, P. Çiragil, A.E Topkaya Z. Kipritçi, S.D Bakirezer Group A					
<b>10.00- 10.50</b>	<b>Lecture</b> Benign Prostatic Hyperplasia-II A.Ç. Çetinel	<b>Lecture</b> Urologic Oncology II A.Ç. Çetinel	<b>Lecture</b> Chronic Kidney Disease A.Özkök	<b>Lecture</b> Pathology of Male Genital System I E. Hacıhasanoğlu	<b>Group B</b>					
<b>11.00- 11.50</b>	<b>Lecture</b> Urologic Emergencies A.Ç. Çetinel	<b>Lecture</b> Estrogens, Progestines and Inhibitors I E. N. Özdamar	<b>Lecture</b> Acid/ Base Balance I A.Özkök	<b>Lecture</b> Pathology of Male Genital System II E. Hacıhasanoğlu	<b>Group C</b>					
<b>12.00- 12.50</b>	<b>Lecture</b> Approach to the Patient with Urinary Tract Symptoms A.Ç. Çetinel	<b>Lecture</b> Estrogens, Progestines and Inhibitors II E. N. Özdamar	<b>Lecture</b> Acid/ Base Balance II A.Özkök	<b>Microbiology Laboratory</b> Diagnostic Tests for Urinary and genital Specimens-1 G. Söyletir, P. Çiragil, A.E Topkaya Z. Kipritçi, S.D Bakirezer	<b>Group D</b>					
<b>12.50 -14.00</b>	<b>LUNCH BREAK</b>									
<b>14.00- 14.50</b>	<b>ICP-CSL</b> Clinical Breast Examination B.K. Aysal/M. Ersan/ E.Özer	<b>ICP-CSL</b> Clinical Breast Examination B.K. Aysal/M. Ersan/ E.Özer	<b>Pathology Laboratory</b> (Urinary System) E. Hacıhasanoğlu	<b>Group A</b>	<b>Group B IL</b>	<b>Group A</b>	<b>ELECTIVE WEEK IV</b>	<b>Independent Learning</b>		
<b>15.00- 15.50</b>	<b>Group A</b> Small Group Study SRPC	<b>Group B</b> ICP	<b>Group C &amp; D</b> IL	<b>Group A IL</b>	<b>Group B IL</b>	<b>Group C ICP</b>	<b>Group D</b> Small Group Study SRPC	<b>Independent Learning</b>	<b>Group B</b>	<b>ELECTIVE WEEK IV</b>
<b>16.00- 16.50</b>								<b>Independent Learning</b>	<b>Group C</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Group D</b>					

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**

**WEEK VI / 10 – 14 Mar 2025**

	<b>Monday 10-Mar-2025</b>	<b>Tuesday 11-Mar-2025</b>	<b>Wednesday 12-Mar-2025</b>	<b>Thursday 13-Mar-2025</b>	<b>Friday 14-Mar-2025</b>
09.00- 09.50	<b>Independent Learning</b>	<b>Lecture</b> Hypothalamic and Pituitary Hormones I <i>E. N. Özdamar</i>	<b>Multidisciplinary Case Discussion Panel</b>	<b>ICP-CSL</b> Physical Examination of the Newborn and Child Patient <i>Ç. Ayanoğlu / M. Berber</i>	<b>Physicians' Day</b>
10.00- 10.50	Pathology Laboratory (Urinary System) <i>E. Hacıhasanoğlu</i> Group B Group A IL	<b>Lecture</b> Hypothalamic and Pituitary Hormones II <i>E. N. Özdamar</i>	<b>Multidisciplinary Case Discussion Panel</b>	Group A ICP-CSL Group B ICP-CSL Group C IL Group D IL	
11.00- 11.50	<b>Lecture</b> Phytotherapy-VII <i>E. Güzelmeriç</i>	<b>Lecture</b> Relation Between Several Variables <i>Ç. Keleş</i>	<b>Lecture</b> Tubulointerstitial Diseases <i>A.Özkök</i>		
12.00- 12.50	<b>Lecture</b> Phytotherapy-VIII <i>E. Güzelmeriç</i>	<b>Lecture</b> Transplantation of Kidney <i>A.Kurt</i>	<b>Lecture</b> Tubulointerstitial Diseases <i>A.Özkök</i>	<b>Independent Learning</b>	
12.50- 14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>ICP-CSL</b> Clinical Breast Examination <i>B.K. Aysal/M. Ersan/ E.Özer</i>	<b>Lecture</b> Nephritic and Nephrotic Syndrome <i>C. Saf</i>	<b>Lecture</b> Genetic disorders of gonadal development <i>A. Ç. Kuşkucu</i>	<b>ICP-CSL</b> Physical Examination of the Newborn and Child Patient <i>Ç. Ayanoğlu / M. Berber</i>	<b>Physicians' Day</b>
15.00- 15.50	Group B Small Group Study SRPC Group A ICP Group C IL Group D IL	<b>Lecture</b> Pregnancy follow-up in primary care <i>D. Altıparmak</i>	<b>Lecture</b> Genetic disorders of gonadal development <i>A. Ç. Kuşkucu</i>	Group A IL Group B IL Group C ICP-CSL Group D ICP-CSL	
16.00- 16.50		<b>Lecture</b> Pathology of Bladder <i>E. Hacıhasanoğlu</i>	<b>Lecture</b> Approach to menopause and osteoporosis in primary care <i>T. Sadıkoğlu</i>		
17.00-17.50	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Pregnancy & Placenta <i>F. Özkan</i>	<b>Independent Learning</b>	<b>Independent Learning</b>	

**COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS**

**WEEK VII / 17 – 21 Mar 2025**

	Monday 17-Mar-2025	Tuesday 18-Mar-2025	Wednesday 19-Mar-2025	Thursday 20-Mar-2025	Friday 21-Mar-2025	
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning	
10.00- 10.50					COMMITTEE EXAM	
11.00- 11.50						
12.00- 12.50					Program Evaluation Session Committee IV Coordination Committee Members	
12.50- 14.00	LUNCH BREAK					
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	ELECTIVE WEEK V	Independent Learning
15.00- 15.50						
16.00- 16.50					Independent Learning	
17.00-17.50						ELECTIVE WEEK V

**COMMITTEE V - NERVOUS SYSTEM AND PSYCHIATRY**

**DISTRIBUTION of LECTURE HOURS**

**March 24, 2025– May 9, 2025**

**COMMITTEE DURATION: 7 WEEKS**

COURSES							
	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC./LAB.	SMALL GROUP DISCUSSION	DISCUSSION	TOTAL
	<b>DISCIPLINE/COMPONENTS</b>						
	NEUROSURGERY	NRS	15	2GrX2H	0	0	17
	NEUROLOGY	NR	14	2GrX2H	0	0	16
	PHARMACOLOGY	PC	17	0	0	0	17
	PATHOLOGY	PT	11	2GrX1H	0	0	12
	PSYCHIATRY	PCH	12	0	0	0	12
	PEDIATRICS	PED	4	0	0	0	4
	PUBLIC HEALTH	PH	4	0	0	0	4
	FAMILY MEDICINE	FM	3	0	0	0	3
	BIOSTATISTICS	BS	3	0	0	0	3
<b>MED 302</b>	CHILD PSYCHIATRY	C-PCH	3	0	0	0	3
	MEDICAL GENETICS	MG	3	0	0	0	3
	OPHTALMOLOGY	OPT	3	0	0	0	3
	PATHOPHYSIOLOGY	PP	2	0	0	0	2
	IMMUNOLOGY	IMM	2	0	0	0	2
	INFECTIOUS DISEASES	ID	2	0	0	0	2
	MEDICAL MICROBIOLOGY	MM	6	0	0	0	6
	RADIOLOGY	RAD	1	0	0	0	1
	EMERGENCY MEDICINE	EM	1	0	0	0	1
	GENERAL SURGERY	GS	1	0	0	0	1
	INTERDISCIPLINARY (NRS,NR,PCH)	MCDP	0	0	0	2	2
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC	0	0	4Grx2H	0	2
	<b>TOTAL</b>		107	5	2	2	116
	<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III	0	4GrX6H		
	<b>INDEPENDENT LEARNING HOURS</b>						<b>93</b>

**Coordination Committee**

<b>HEAD</b>	Okan Taycan, MD, Assoc. Prof.
<b>SECRETARY</b>	Erdem Söztutar, MD, Assist. Prof.
<b>MEMBER</b>	Berrin Aktekin, MD, Prof.
<b>MEMBER</b>	Özge Yabaş Kızıloğlu, MD, Assoc. Prof.
<b>MEMBER</b>	Yüksel Dede, MD



**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY  
LECTURERS**

<b>MED 302 INTRODUCTION to CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>NEUROLOGY</b>	Berrin Aktekin, MD, Prof. Rana Karabudak, MD, Prof. Halide Rengin Bilgen, MD, Assist. Prof. Yüksel Dede, MD
<b>PSYCHIATRY</b>	Okan Taycan, MD, Prof. Naz Berfu Akbaş, MD, Assoc. Prof
<b>CHILD PSYCHIATRY</b>	Oğuzhan Zahmacıoğlu, MD, Assoc. Prof
<b>NEUROSURGERY</b>	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Ahmet Hilmi Kaya, MD, Prof. Aikaterini Panteli, MD, Assist. Prof.
<b>PATHOLOGY</b>	Aydın Sav, MD, Prof.
<b>PATHOPHYSIOLOGY</b>	Mehtap Kaçar, MD, PhD, Prof.
<b>PHARMACOLOGY</b>	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof. Cenk Andaç, PhD, Assist. Prof.
<b>PEDIATRICS</b>	Haluk Aydın Topaloğlu, MD, Prof. Manolya Kara, MD, Assoc. Prof. Mustafa Berber, MD, Assist. Prof. Fulya Coşkunol, MD
<b>PUBLIC HEALTH</b>	Hale Arık Taşyikan, MD, Assist. Prof.
<b>FAMILY MEDICINE</b>	Tümay Sadıkoğlu, MD, Assist. Prof.
<b>RADIOLOGY</b>	Gazanfer Ekinci, MD, Prof.
<b>MEDICAL GENETICS</b>	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
<b>INFECTIOUS DISEASES</b>	Meral Sönmezoğlu, MD, Prof.
<b>MEDICAL MICROBIOLOGY</b>	Güner Söyletir, MD, Prof.
<b>OPHTHALMOLOGY</b>	Özge Yabaş Kızıloğlu, MD, Assoc. Prof.
<b>BIostatISTICS</b>	Çiğdem Keleş, PhD, Assist. Prof.
<b>EMERGENCY MEDICINE</b>	Sezgin Sarıkaya, MD, Prof.
<b>IMMUNOLOGY</b>	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
<b>GENERAL SURGERY</b>	Alper Kurt , MD
<b>OTHER COURSES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.

<b>MED 303 INTRODUCTION to CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>CLINICAL SKILLS LAB</b>	Okan Taycan, MD, Prof. Oğuzhan Zahmacıoğlu, MD, Assoc. Prof. Hakan Atalay, MD, Assoc. Prof. Serhat Tunç, MD, Assoc. Prof. Halide Rengin Bilgen Akdeniz, MD, Assist. Prof. Alper Kurt, MD

## **COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY AIMS and LEARNING OBJECTIVES**

### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in nervous and psychiatric clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to nervous and psychiatric clinical conditions, this committee aims to convey necessary knowledge on ethical problems, biostatistical knowledge required in the design of medical research and to convey necessary knowledge on the genetic basis of clinical conditions, and immune response.

### **LEARNING OBJECTIVES OF NERVOUS SYSTEM and PSYCHIATRY**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or life threatening or constitute an emergency, at the primary health care level; at the end of this committee, the student should be able to:

- N1. to recall knowledge on anatomy, histology, and physiology of nervous system,
- N2. to define etiopathogenesis of clinical conditions related to nervous system and psychiatry,
- N3. to explain epidemiology of clinical conditions related to nervous system and psychiatry,
- N4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
- N5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs, and findings in clinical conditions related to nervous system and psychiatry,
- N6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry,
- N7. to convey knowledge on pharmacology of drugs that are effective on nervous system or on clinical conditions involving nervous system and psychiatry,
- N8. to convey necessary knowledge on genetic basis of clinical conditions related to nervous system and psychiatry,
- N9. to define design and biostatistical analysis of survival research,
- N10. to define ethical problems encountered in health care service and utilization, and on principles of solutions,

**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
N7	PC	E. Genç	14	5	5	24
		E. N. Özdamar				
		C. Andaç				
N1 – N6	NRS	M.G. Yaşargil	12	4	4	20
		U. Türe				
		A.H. Kaya				
		A. Panteli				
N1 – N6	NR	B. Aktekin	11	4	4	19
		R. Karabudak				
		H. R. Bilgen Akdeniz				
		Y. Dede				
N1 – N6	PCH	O. Taycan	10	4	4	18
		N.B. Akbaş				
N2	PT	A. Sav	9	3	3	15
N1 – N6	PED	H.A.Topaloğlu	3	1	1	5
		M. Berber				
		M. Kara				
N5	IMM	G. Y. Demirel	2	1	1	4
N3 – N4	PH	H.A Taşyikan	3	1	1	5
N6	FM	T.Sadıkoğlu	3	1	1	5
N9	BS	Ç. Keleş	3	1	1	5
N8	MG	A.Ç. Kuşkucu	3	1	1	5
N1 – N6	C-PCH	O. Zahmacioğlu	3	1	1	5
N1 – N6	OPT	Ö. Yabaş Kızıloğlu	3	1	1	5
N5	PP	M. Kaçar	2	1	1	4
N5	ID	M. Sönmezoğlu	2	1	1	4
N2,N6	MM	G. Söyletir	4	2	2	8
N5	RAD	G. Ekinci	1	0	0	1
N5	EM	S. Sarıkaya	1	0	0	1
N5	GS	A.Kurt	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>32</b>	<b>32</b>	<b>154</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
N1 – N6	NR	B. Aktekin	2	-	-	2
N1 – N6	PCH	O. Taycan/N.B. Akbaş	2	-	-	2
N1 – N6	NRS	U. Türe	1	-	-	1
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*32** out of 200 FE and ICE MCQs will be from Committee V (Each question is worth 0.5 points).

**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY**  
**WEEK 1 / 24 – 28 Mar 2025**

	<b>Monday 24-Mar-2025</b>	<b>Tuesday 25-Mar-2025</b>	<b>Wednesday 26-Mar-2025</b>	<b>Thursday 27-Mar-2025</b>	<b>Friday 28-Mar-2025</b>	
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Myelin & Neuronal Storage Diseases I <i>A. Sav</i>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Lecture</b> Pharmacological Approach to Parkinsonism & Other Movement Disorders I <i>E. Genç</i>	
<b>10.00- 10.50</b>	<b>Lecture</b> Signs and Symptoms in Neurology <i>B. Aktekin</i>	<b>Lecture</b> Pathology of Myelin & Neuronal Storage Diseases II <i>A. Sav</i>	<b>Lecture</b> Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient <i>A. Panteli</i>	<b>Lecture</b> Surgical Neuroanatomy <i>U. Türe</i>	<b>Lecture</b> Pharmacological Approach to Parkinsonism & Other Movement Disorders II <i>E. Genç</i>	
<b>11.00- 11.50</b>	<b>Lecture</b> Cranial Nerves I <i>B. Aktekin</i>	<b>Lecture</b> Developmental Disorders of CNS <i>A. Sav</i>	<b>Lecture</b> Spinal Trauma in Neurosurgery <i>A. Panteli</i>	<b>Lecture</b> Cerebrovascular Diseases in Neurosurgery I <i>U. Türe</i>	<b>Lecture</b> Headache in Neurologic Patient <i>Y. Dede</i>	
<b>12.00- 12.50</b>	<b>Lecture</b> Cranial Nerves II <i>B. Aktekin</i>	<b>Lecture</b> Introduction to Central Nervous System Pharmacology <i>E. Genç</i>	<b>Lecture</b> Cranial Trauma in Neurosurgery <i>A. Panteli</i>	<b>Lecture</b> Cerebrovascular Diseases in Neurosurgery II <i>U. Türe</i>	<b>Lecture</b> Extrapyramidal System Disorders <i>Y. Dede</i>	
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>					
<b>14.00- 14.50</b>	<b>Lecture</b> Epilepsy <i>B. Aktekin</i>	Introduction to Neuroimmunology <i>R. Karabudak</i>	<b>Lecture</b> Public Health and Aging I <i>H. A. Taşyikan</i>	<b>Lecture</b> Intracranial Tumors I <i>M. Gazi Yaşargil</i>	<b>ELECTIVE WEEK VI</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Peripheral Nerve Disorders <i>B. Aktekin</i>	<b>Lecture</b> Demyelinating Disorders I <i>R. Karabudak</i>	<b>Lecture</b> Public Health and Aging II <i>H. A. Taşyikan</i>	<b>Lecture</b> Intracranial Tumors II <i>M. Gazi Yaşargil</i>		
<b>16.00- 16.50</b>	<b>Lecture</b> Pathophysiology of Nervous System Diseases I <i>M. Kaçar</i>	<b>Lecture</b> Demyelinating Disorders II <i>R. Karabudak</i>	<b>Lecture</b> Neuroimmunological Disorders <i>G. Yanıkkaya Demirel</i>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>ELECTIVE WEEK VI</b>
<b>17.00-17.50</b>	<b>Lecture</b> Pathophysiology of Nervous System Diseases II <i>M. Kaçar</i>	<b>Lecture</b> Approach to Intoxicated Patient <i>S. Sarıkaya</i>	<b>Lecture</b> Neuroimmunological Disorders <i>G. Yanıkkaya Demirel</i>	<b>Independent Learning</b>		

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY  
WEEK II / 31 Mar – 4 Apr 2025**

	<b>Monday 31-Mar-2025</b>	<b>Tuesday 1-Apr-2025</b>	<b>Wednesday 2-Apr-2025</b>	<b>Thursday 3-Apr-2025</b>	<b>Friday 4-Apr-2025</b>	
<b>09.00- 09.50</b>	<b>RAMADAN FEAST</b>	<b>RAMADAN FEAST</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	
<b>10.00- 10.50</b>						
<b>11.00- 11.50</b>						
<b>12.00- 12.50</b>						
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>					
<b>14.00- 14.50</b>	<b>RAMADAN FEAST</b>	<b>RAMADAN FEAST</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>ELECTIVE WEEK VII</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>						
<b>16.00- 16.50</b>					<b>Independent Learning</b>	<b>ELECTIVE WEEK VII</b>
<b>17.00-17.50</b>						

**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY**  
**WEEK III / 7 – 11 Apr 2025**

	Monday 7-Apr-2025	Tuesday 8-Apr-2025	Wednesday 9-Apr-2025	Thursday 10-Apr-2025	Friday 11-Apr-2025
09.00- 09.50	<b>Lecture</b> Hydrocephalus A. H. Kaya	<b>Pathology Laboratory (Nervous System)</b> A Sav. <b>Group A</b> <b>Group B</b>	<b>Neurosurgery Clinical Training</b> A. H. Kaya A. Panteli <b>Neurology Clinical Training</b> H.R. Bilgen Akdeniz	<b>ICP-CSL</b> Neurological Examination & Psychiatric Examination H. R. Bilgen Akdeniz / O. Taycan / O. Zahmacioğlu / H. Atalay	<b>Neurology Clinical Training</b> Y. Dede <b>Neurosurgery Clinical Training</b> A. H. Kaya A. Panteli
10.00- 10.50	<b>Lecture</b> Functional Neurosurgery A. H. Kaya	<b>Lecture</b> Antiepileptics E. Genç	<b>Group A</b> <b>Group B</b> <b>Group C</b> <b>Group D</b>	<b>Group A IIL</b> <b>Group B IIL</b> <b>Group C ICP</b> <b>Group D Small Group Study SRPC</b>	<b>Group A</b> <b>Group B</b> <b>Group C</b> <b>Group D</b>
11.00- 11.50	<b>Lecture</b> Spinal Cord Compression and Spinal Tumors A. H. Kaya	<b>Lecture</b> Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu	<b>Lecture</b> Herpes Viruses G. Söyletir		<b>Lecture</b> Paralytic Strabismus and Nistagmus Ö. Yabaş Kızıoğlu
12.00- 12.50	<b>Lecture</b> Degenerative Diseases of the Spine and the Spinal Cord A. H. Kaya	<b>Lecture</b> Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu	<b>Lecture</b> Herpes Viruses G. Söyletir	<b>Independent Learning</b>	<b>Lecture</b> Conventional Neuroradiological Examinations G. Ekinçi
12.50 – 14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>Lecture</b> Neurodegenerative Disorders I A. Sav	<b>Lecture</b> Diseases of Optic Nerves and Visual Fields Ö. Yabaş Kızıoğlu	<b>Lecture</b> Neurosurgical Infections A. Panteli	<b>Lecture</b> Culture, Health, and Illness H. A. Taşyikan	<b>ELECTIVE WEEK VIII MIDTERM EXAM</b>
15.00- 15.50	<b>Lecture</b> Neurodegenerative Disorders II A. Sav	<b>Lecture</b> Pupilla Ö. Yabaş Kızıoğlu	<b>Lecture</b> Pediatric Neurosurgery A. Panteli	<b>Lecture</b> Behavioral Determinants of Health and Disease H. A. Taşyikan	
16.00- 16.50	<b>Lecture</b> Microbiological approach to CNS infections G. Söyletir	<b>Lecture</b> Neurological Emergencies R. Bilgen	<b>Lecture</b> Peripheral Nerve Compression Syndromes A. Panteli	<b>Lecture</b> Cerebral Lobes and their Disorders H.R. Bilgen Akdeniz	<b>Independent Learning</b>
17.00-17.50	<b>Lecture</b> Microbiological approach to CNS infections G. Söyletir	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Lecture</b> Dementia H.R. Bilgen Akdeniz	

**COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY**  
**WEEK IV / 14 – 18 Apr 2025**

	<b>Monday 14-Apr-2025</b>	<b>Tuesday 15-Apr-2025</b>	<b>Wednesday 16-Apr-2025</b>	<b>Thursday 17-Apr-2025</b>	<b>Friday 18-Apr-2025</b>	
<b>09.00- 09.50</b>	<b>Lecture</b> Tumors of CNS I <i>A. Sav</i>	<b>Lecture</b> Psychiatric Epidemiology and Classification <i>N. B. Akbaş</i>	<b>Lecture</b> Introduction to Child and Adolescent Psychiatry <i>O. Zahmacioğlu</i>	<b>Lecture</b> Mental Development in Childhood and Adolescence <i>O. Zahmacioğlu</i>	<b>Lecture</b> Genetic Aspects of Psychiatric Disorders <i>A. Ç. Kuşkucu</i>	
<b>10.00- 10.50</b>	<b>Lecture</b> Tumors of CNS II <i>A. Sav</i>	<b>Lecture</b> Anxiety Disorders: An Introduction <i>N. B. Akbaş</i>	<b>Lecture</b> Common Childhood Psychiatric Problems <i>O. Zahmacioğlu</i>	<b>Lecture</b> Neurodegenerative Disorders <i>H. A. Topaloğlu</i>	<b>Lecture</b> Antidepressant Drugs <i>E. N. Özdamar</i>	
<b>11.00- 11.50</b>	<b>Lecture</b> Introduction to Psychiatry <i>O. Taycan</i>	<b>Lecture</b> Schizophrenia Spectrum and Other Psychotic Disorders I <i>O. Taycan</i>	<b>Lecture</b> Neuroscience I <i>N. B. Akbaş</i>	<b>Lecture</b> Cerebral Malformations <i>H. A. Topaloğlu</i>	<b>Lecture</b> Opioid Analgesics & Antagonists I <i>E. Genç</i>	
<b>12.00- 12.50</b>	<b>Lecture</b> Psychiatric Interview, History <i>O. Taycan</i>	<b>Lecture</b> Schizophrenia Spectrum and Other Psychotic Disorders II <i>O. Taycan</i>	<b>Lecture</b> Neuroscience II <i>N. B. Akbaş</i>	<b>Lecture</b> Mental and Motor Development <i>H. A. Topaloğlu</i>	<b>Lecture</b> Opioid Analgesics & Antagonists II <i>E. Genç</i>	
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>					
<b>14.00- 14.50</b>	<b>Lecture</b> Signs and Symptoms in Psychiatry <i>O. Taycan</i>	<b>Lecture</b> Bipolar Disease & Lithium <i>E. N. Özdamar</i>	<b>Lecture</b> Mood Disorders I <i>N. B. Akbaş</i>	<b>Lecture</b> Infectious Disease of the Nervous System <i>M. Kara</i>	<b>ELECTIVE WEEK IX</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Developmental Psychopathology: Risk and Protective Factors in Mental Development <i>O. Taycan</i>	<b>Lecture</b> Antipsychotic Drugs <i>E. N. Özdamar</i>	<b>Lecture</b> Mood Disorders II <i>N. B. Akbaş</i>	<b>Lecture</b> Cerebrovascular Disease <i>Y. Dede</i>		
<b>16.00- 16.50</b>	<b>Lecture</b> Persistent Viral Infections of the CNS and Prions <i>G. Söyletir</i>	<b>Lecture</b> Cranial Trauma & Intracranial Hemorrhage I <i>A. Sav</i>	<b>Lecture</b> Depression in Primary Care <i>T. Sadıkoğlu</i>	<b>Lecture</b> Drug Dependence & Abuse <i>C. Andaç</i>	<b>Independent Learning</b>	<b>ELECTIVE WEEK IX</b>
<b>17.00-17.50</b>	<b>Lecture</b> Arthropod-Borne and Other Zoonotic Viruses (including Rabies) <i>G. Söyletir</i>	<b>Lecture</b> Cranial Trauma & Intracranial Hemorrhage II <i>A. Sav</i>	<b>Lecture</b> Approach to the Patient with Dementia in Primary Care <i>T. Sadıkoğlu</i>	<b>Lecture</b> The Alcohols <i>C. Andaç</i>		

**COMMITTEE V - NERVOUS SYSTEM AND PSYCHIATRY  
WEEK V / 21 – 25 Apr 2025**

	<b>Monday 21-Apr-2025</b>	<b>Tuesday 22-Apr-2025</b>	<b>Wednesday 23-Apr-2025</b>	<b>Thursday 24-Apr-2025</b>	<b>Friday 25-Apr-2025</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Approach to headache in primary care <i>T. Sadıkoğlu</i>	<b>Independent Learning</b>	<b>NATIONAL HOLIDAY</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Antimigraine Drugs <i>E. N. Özdamar</i>	<b>Multidisciplinary Case Discussion Panel</b>		<b>ICP-CSL</b> Neurological Examination & Psychiatric Examination <i>H. R. Bilgen Akdeniz / O. Taycan / O. Zahmacioğlu / H. Atalay</i>	<b>Lecture</b> CNS Stimulants and Hallucinogenic Drugs <i>C. Andaç</i>
<b>11.00- 11.50</b>	<b>Lecture</b> Analysis of Survival Studies I <i>Ç. Keleş</i>	<b>Multidisciplinary Case Discussion Panel</b>		<b>Group A ICP</b>	<b>Lecture</b> Local Anesthetics <i>E. Genç</i>
<b>12.00- 12.50</b>	<b>Lecture</b> Analysis of Survival Studies II <i>Ç. Keleş</i>	<b>Lecture</b> Design of Survival Studies <i>Ç. Keleş</i>		<b>Group B Small Group Study</b>	<b>Lecture</b> General Anesthetics <i>E. Genç</i>
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Infectious Diseases of CNS I <i>A. Sav</i>	<b>Lecture</b> General Physical Examination <i>A. Kurt</i>	<b>NATIONAL HOLIDAY</b>	<b>ICP-CSL</b> General Physical Examination <i>A. Kurt</i>	<b>ELECTIVE WEEK X</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Infectious Diseases of CNS II <i>A. Sav</i>	<b>Lecture</b> Acute and Chronic Meningitis, Encephalitis I <i>M. Sönmezoğlu</i>		<b>Group A ICP</b>	<b>Independent Learning</b>
<b>16.00- 16.50</b>	<b>Lecture</b> Sedative / Hypnotic Drugs I <i>E. Genç</i>	<b>Lecture</b> Acute and Chronic Meningitis, Encephalitis II <i>M. Sönmezoğlu</i>		<b>Group B IL</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Lecture</b> Sedative / Hypnotic Drugs II <i>E. Genç</i>	<b>Independent Learning</b>		<b>Group C IL</b>	<b>ELECTIVE WEEK X</b>
				<b>Group D IL</b>	
				<b>Independent Learning</b>	



**COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK VI / 28 Apr – 2 May 2025**

	Monday 28-Apr-2025	Tuesday 29-Apr-2025	Wednesday 30-Apr-2025	Thursday 1-May-2025	Friday 2-May-2025	
09.00- 09.50	OSCE EXAM	<b>ICP-CSL</b> Neurological Examination & Psychiatric Examination H. R. Bilgen Akdeniz / O. Taycan / O. Zahmacioğlu / H. Atalay	<b>ICP-CSL</b> General Physical Examination A. Kurt	LABOR DAY	<b>ICP-CSL</b> General Physical Examination A. Kurt	
10.00- 10.50		Group A IL Group B IL Group C Small Group Study SRPC Group D ICP	Group A IL Group B IL Group C IL Group D ICP		Group A IL Group B IL Group C ICP Group D IL	
11.00- 11.50						
12.00- 12.50		Independent Learning	Independent Learning		Independent Learning	
12.50 – 14.00	LUNCH BREAK					
14.00- 14.50	OSCE EXAM	<b>ICP-CSL</b> General Physical Examination A. Kurt	<b>ICP-CSL</b> Neurological Examination & Psychiatric Examination H. R. Bilgen Akdeniz / O. Taycan / O. Zahmacioğlu / H. Atalay	LABOR DAY	<b>ELECTIVE WEEK XI</b>  Independent Learning	
15.00- 15.50		Group A IL Group B ICP Group C IL Group D IL	Group A Small Group Study Group B ICP Group C IL Group D IL		Independent Learning	<b>ELECTIVE WEEK XI</b>
16.00- 16.50						
17.00-17.50		Independent Learning	Independent Learning		Independent Learning	

**COMMITTEE V - NERVOUS SYSTEM AND PSYCHIATRY  
WEEK VII / 5 – 9 May 2025**

	<b>Monday 5-May-2025</b>	<b>Tuesday 6-May-2025</b>	<b>Wednesday 7-May-2025</b>	<b>Thursday 8-May-2025</b>	<b>Friday 9-May-2025</b>	
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning	
10.00- 10.50					COMMITTEE EXAM	
11.00- 11.50					Program Evaluation Session Committee V Coordination Committee Members	
12.00- 12.50						
12.50 – 14.00	LUNCH BREAK					
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	ELECTIVE WEEK XII	Independent Learning
15.00- 15.50					Independent Learning	ELECTIVE WEEK XII
16.00- 16.50						
17.00-17.50						

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM**

**DISTRIBUTION of LECTURE HOURS**

**May 12, 2025 – June 19, 2025**

**COMMITTEE DURATION: 6 WEEKS**

<b>COURSES</b>							
	<b>INTRODUCTION to CLINICAL SCIENCES</b>	<b>ABBR.</b>	<b>THEO.</b>	<b>PRAC./LAB.</b>	<b>SMALL GROUP DISCUSSION</b>	<b>DISCUSSION</b>	<b>TOTAL</b>
	<b>DISCIPLINE/COMPONENTS</b>						
<b>MED 302</b>	ORTHOPAEDICS & TRAUMATOLOGY	ORT	19	0	0	0	<b>19</b>
	PATHOLOGY	PT	13	2Gx1H	0	0	<b>14</b>
	RHEUMATOLOGY	RHE	9	0	0	0	<b>9</b>
	PHARMACOLOGY	PC	5	0	0	0	<b>5</b>
	PHYSICAL MEDICINE AND REHABILITATION	PMR	5	0	0	0	<b>5</b>
	MEDICAL MICROBIOLOGY	MM	5	0	0	0	<b>5</b>
	PUBLIC HEALTH	PH	4	0	0	0	<b>4</b>
	BIOSTATISTICS	BS	3	0	0	0	<b>3</b>
	PATHOPHYSIOLOGY	PP	2	0	0	0	<b>2</b>
	IMMUNOLOGY	IMM	2	0	0	0	<b>2</b>
	MEDICAL GENETICS	MG	2	0	0	0	<b>2</b>
	EMERGENCY MEDICINE	EM	2	0	0	0	<b>2</b>
	RADIOLOGY	RAD	1	0	0	0	<b>1</b>
	INTERDISCIPLINARY (ORT, RHE, PMR)	MCDP	0	0	0	2	<b>2</b>
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC	0	0	4GrX4H	0	<b>4</b>
<b>TOTAL</b>			<b>72</b>	<b>1</b>	<b>4</b>	<b>2</b>	<b>79</b>
<b>MED 303</b>	INTRODUCTION to CLINICAL PRACTICE III	ICP III		4GrX6H			<b>6</b>
<b>INDEPENDENT LEARNING</b>							<b>146</b>

**Coordination Committee**

<b>HEAD</b>	Müge Bıçakçığıl Kalaycı, MD, Assoc. Prof
<b>SECRETARY</b>	Yeşim Özarda, MD, Prof.
<b>MEMBER</b>	Gökşen Gökşenoğlu, MD, Assoc. Prof.
<b>MEMBER</b>	Burak Çağrı Aksu, MD, Assist. Prof.
<b>MEMBER</b>	Didem Seven, PhD, Instructor

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
LECTURERS**

<b>MED 302 INTRODUCTION to CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>FACULTY</b>
ORTHOPAEDICS & TRAUMATOLOGY	Gökhan Meriç, MD, Prof. Hasan Bombacı, MD, Prof. Budak Akman, MD, Prof. Burak Çağrı Aksu, MD, Assist. Prof. Ömer Yonga, MD
PHYSICAL MEDICINE AND REHABILITATION	Gökşen Gökşenoğlu, MD, Assoc. Prof.
RHEUMATOLOGY	Müge Bıçakçığıl Kalaycı, MD, Prof
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof. Latife Arzu Aral, MD, PhD, Prof. Başak Aru, PhD, Assist. Prof.
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Assist. Prof
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assoc. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Prof.
BIOSTATISTICS	Çiğdem Keleş, PhD, Assist. Prof.
MEDICAL MICROBIOLOGY	Güner Söyletir, MD, Prof. Nilgün Çerikçioğlu, MD, Prof.
<b>OTHER COURSES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Aylin Yaba Uçar, PhD, Prof.

<b>MED 303 INTRODUCTION to CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Gökhan Meriç, MD, Prof. Bilge Kağan Aysal, MD, Assoc. Prof. Burak Çağrı Aksu, MD, Assist. Prof. Mert Ersan, MD Emre Özer, MD

## **COMMITTEE VI - MUSCULOSKELETAL SYSTEM**

### **AIMS and LEARNING OBJECTIVES**

#### **AIMS**

The aim of this committee is to convey fundamental knowledge on the prevention measures, etiology, pathophysiology, clinical symptoms and signs, differential diagnosis and pharmacology of drugs used in musculoskeletal system clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency. In addition to musculoskeletal clinical conditions, this committee aims to convey necessary knowledge on biostatistical knowledge required in the design of medical research and to convey necessary knowledge on genetic basis of clinical conditions and immune response.

#### **LEARNING OBJECTIVES OF MUSCULOSKELETAL SYSTEM**

In evidence based manner, and related to conditions which are frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency, at the primary health care level; at the end of this committee, the student should be able to:

- M1. to recall knowledge on histology and physiology of musculoskeletal system,
- M2. to define etiopathogenesis of clinical conditions related to musculoskeletal system
- M3. to explain epidemiology of clinical conditions related to musculoskeletal system
- M4. to explain prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
- M5. to explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions related to musculoskeletal system,
- M6. to explain together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system,
- M7. to convey knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving musculoskeletal system,
- M8. to convey necessary knowledge on genetic basis of clinical conditions,
- M9. to explain principles of random sampling, confidence interval, and power analysis

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM**  
**COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE VI - MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
M1-M6	ORT	B. Ç. Aksu	24	5	5	34
		B.Akman				
		G. Meriç				
		Ö.Yonga				
		H. Bombacı				
M2	PT	F. Özkan	16	4	4	24
		A. Sav				
M1-M6	RHE	M. Bıçakçığıl Kalaycı	11	3	3	17
M4-M5	PMR	G.Gökşenoğlu	6	1	1	8
M7	PC	E. Genç	6	1	1	8
		E. N. Özdamar				
M2,M6	MM	G. Söyletir	6	1	1	8
		N. Çerikçioğlu				
M4	PH	H.A.Taşyikan	5	1	1	7
M5	IMM	G. Y. Demirel	3	1	1	5
M9	BS	Ç. Keleş	3	1	1	5
M2	PP	M. Kaçar	3	1	1	5
M8	MG	A.Ç. Kuşkucu	3	1	1	5
M5-M6	EM	S. Sarıkaya	3	1	1	5
M6	RAD	N. Taşdelen	1	0	0	1
<b>TOTAL</b>			<b>90</b>	<b>21</b>	<b>21</b>	<b>132</b>
LEARNING OBJECTIVE	DISCIPLINE	LECTURER / INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
M1-M6	RHE	M. Bıçakçığıl Kalaycı	2	-	-	2
M1-M6	ORT	B.Ç. Aksu	2	-	-	2
M1-M6	PMR	G.Gökşenoğlu	1	-	-	1
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**Abbreviations**

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*21** out of 200 FE and ICE MCQs will be from Committee VI (Each question is worth **0.5** pts).

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
WEEK I / 12 -16 May 2025**

	Monday 12-May-2025	Tuesday 13-May-2025	Wednesday 14-May-2025	Thursday 15-May-2025				Friday 16-May-2025	
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	ICP-CSL (Physical Examination of the Musculoskeletal System) G. Meriç / B.Ç. Aksu				Lecture Frostbite / Burns S. Sarıkaya	
10.00- 10.50	Independent Learning	Lecture Degenerative Joint Disease F. Özkan	Osteoporosis Management G.Gökşenoğlu	Group A ICP	Group B Small Group Study SRPC	Group C IL	Group D IL	Lecture Initial Approach to Trauma Patient S. Sarıkaya	
11.00- 11.50	Lecture Superficial/Subcutaneous Mycosis N.Çerikçioğlu	Lecture Tumors of Soft Tissues I F. Özkan	Lecture Osteoporosis and Osteoarthritis Treatment, Rehabilitation G.Gökşenoğlu					Lecture Bone and Joint Infections A. Sav	
12.00- 12.50	Lecture Superficial/Subcutaneous Mycosis N.Çerikçioğlu	Lecture Tumors of Soft Tissues II F. Özkan	Lecture Soft Tissue Pain G.Gökşenoğlu	Lecture Power Analysis and Sample Size Calculation I Ç. Keleş				Lecture Myopathies A. Sav	
12.50 – 14.00	LUNCH BREAK								
14.00- 14.50	Lecture Exanthematous viral infections and mumps G.Söyletir	Lecture Spondylarthropaties M. Bıçakçığıl Kalaycı	Lecture Foot Deformities B. Ç. Aksu	Lecture Introduction to Musculoskeletal System G. Meriç				ELECTIVE WEEK XIII	Independent Learning
15.00- 15.50	Lecture Exanthematous viral infections and mumps G.Söyletir	Lecture Inflammatory Polyarthritis & Rheumatoid Arthritis M. Bıçakçığıl Kalaycı	Lecture Spinal Trauma B.Ç. Aksu	Lecture Traumatic Dislocations G. Meriç					
16.00- 16.50	Independent Learning	Lecture Miscellaneous Rheumatological Disorders I M. Bıçakçığıl Kalaycı	Independent Learning	Lecture Congenital & Metabolic Diseases of Bone I A. Sav				Independent Learning	ELECTIVE WEEK XIII
17.00-17.50	Independent Learning	Lecture Miscellaneous Rheumatological Disorders II M. Bıçakçığıl Kalaycı	Independent Learning	Lecture Congenital & Metabolic Diseases of Bone II A. Sav					

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
WEEK II / 19-23 May 2025**

	<b>Monday 19-May-2025</b>	<b>Tuesday 20-May-2025</b>	<b>Wednesday 21-May-2025</b>				<b>Thursday 22-May-2025</b>	<b>Friday 23-May-2025</b>	
09.00- 09.50	<b>National Holiday</b>	<b>Lecture</b> Osteomyelitis H. Bombacı	<b>ICP-CSL</b> Suturing Technique M. Ersan / E. Özer / B. K. Aysal				<b>Lecture</b> Lower Extremity Trauma B.Ç.Aksu	<b>Independent Learning</b>	
10.00- 10.50		<b>Lecture</b> Septic Arthritis H. Bombacı	<b>Group A</b> Small Group Study SRPC	<b>Group B</b> ICP	<b>Group C</b> IL	<b>Group D</b> IL	<b>Lecture</b> Spinal Deformities B.Akman	<b>Lecture</b> Miscellaneous Rheumatological Disorders III M. Bıçakçığıl Kalaycı	
11.00- 11.50		<b>Lecture</b> Development Dysplasia of the Hip H. Bombacı					<b>Lecture</b> Upper Extremity Trauma Ö. Yonga	<b>Lecture</b> Vasculitis I M. Bıçakçığıl Kalaycı	
12.00- 12.50		<b>Lecture</b> Principles of Fracture Healing H. Bombacı	<b>Independent Learning</b>				<b>Lecture</b> Imaging of Musculoskeletal System N. Taşdelen	<b>Lecture</b> Vasculitis II M. Bıçakçığıl Kalaycı	
12.50 – 14.00	<b>LUNCH BREAK</b>								
14.00- 14.50	<b>National Holiday</b>	<b>Lecture</b> Pathophysiology of Musculoskeletal System Disorders I M. Kaçar	<b>ICP-CSL</b> Physical Examination of the Musculoskeletal System G. Meriç / B.Ç. Aksu				<b>Lecture</b> Vasculitis I A. Sav	<b>ELECTIVE WEEK XIV</b>	<b>Independent Learning</b>
15.00- 15.50		<b>Lecture</b> Pathophysiology of Musculoskeletal System Disorders II M. Kaçar	<b>Group A</b> IL	<b>Group B</b> IL	<b>Group C</b> Small Group Study SRPC	<b>Group D</b> ICP	<b>Lecture</b> Vasculitis II A. Sav		
16.00- 16.50		<b>Lecture</b> Bacterial and Mycobacterial skin and soft tissue infections G.Söyletir					<b>Lecture</b> Bone Tumors I A. Sav	<b>Independent Learning</b>	<b>ELECTIVE WEEK XIV</b>
17.00-17.50		<b>Independent Learning</b>	<b>Independent Learning</b>				<b>Lecture</b> Bone Tumors II A. Sav		



**COMMITTEE VI - MUSCULOSKELETAL SYSTEM**  
**WEEK III / 26-30 May 2025**

	<b>Monday 26-May-2025</b>				<b>Tuesday 27-May-2025</b>		<b>Wednesday 28-May-2025</b>				<b>Thursday 29-May-2025</b>				<b>Friday 30-May-2025</b>			
09.00- 09.50	ICP-CSL Suturing Technique M. Ersan / E. Özer / B. K. Aysal				Lecture Management of the Trauma Patient B.Akman		Lecture Connective Tissue Disorders I M. Bıçakçığıl Kalaycı				Lecture Degenerative Osteoarthritis B. Ç. Aksu				Independent Learning			
10.00- 10.50	Group A IL	Group B IL	Group C ICP	Group D Small Group Study SRPC	Lecture Complications of Fractures B.Akman		Lecture Connective Tissue Disorders II M. Bıçakçığıl Kalaycı				Lecture Osteoporosis B. Ç. Aksu				ICP-CSL Physical Examination of the Musculoskeletal System G. Meriç / B.Ç. Aksu			
11.00- 11.50					Lecture Some Common Problems in Medical Research Ç. Keleş		Lecture Nonsteroidal Antiinflammatory Drugs I E. Genç				Lecture Benign Tumors of Bone Ö.Yonga							
12.00- 12.50	Independent Learning				Lecture Power Analysis and Sample Size Calculation II Ç. Keleş		Lecture Nonsteroidal Antiinflammatory Drugs II E. Genç				Lecture Malignant Tumors of Bone Ö.Yonga				Group A Small Group Study SRPC	Group B ICP	Group C IL	Group D IL
12.50 – 14.00	<b>LUNCH BREAK</b>																	
14.00- 14.50	ICP-CSL Suturing Technique M. Ersan / E. Özer / B. K. Aysal				Lecture Autopsy I A. Sav		ICP-CSL Physical Examination of the Musculoskeletal System G. Meriç / B.Ç. Aksu				ICP-CSL Suturing Technique M. Ersan / E. Özer / B. K. Aysal				ELECTIVE WEEK XIV		Independent Learning	
15.00- 15.50	Group A ICP	Group B Small Group Study SRPC	Group C IL	Group D IL	Lecture Autopsy II A. Sav		Group A IL	Group B IL	Group C ICP	Group D Small Group Study SRPC	Group A IL	Group B IL	Group C Small Group Study SRPC	Group D ICP	ELECTIVE WEEK XIV			
16.00- 16.50					Pathology Laboratory (Musculoskeletal System) E. Hacıhasanoğlu	Group A											Group B IL	Independent Learning
17.00-17.50	Independent Learning				Independent Learning		Independent Learning				Independent Learning				Independent Learning		Independent Learning	

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
WEEK IV / 2-6 Jun 2025**

	<b>Monday 2-Jun-2025</b>	<b>Tuesday 3- Jun-2025</b>	<b>Wednesday 4- Jun-2025</b>	<b>Thursday 5- Jun-2025</b>	<b>Friday 6- Jun-2025</b>
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Religious Holiday</b>
<b>10.00- 10.50</b>					
<b>11.00- 11.50</b>					
<b>12.00- 12.50</b>					
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Religious Holiday</b>	<b>Religious Holiday</b>
<b>15.00- 15.50</b>					
<b>16.00- 16.50</b>					
<b>17.00-17.50</b>					

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
WEEK V / 9-13 Jun 2025**

	Monday 9-Jun-2025	Tuesday 10- Jun-2025	Wednesday 11- Jun-2025	Thursday 12- Jun-2025	Friday 13- Jun-2025
09.00- 09.50	<b>Religious Holiday</b>	<b>Independent Learning</b>	<b>Lecture</b> Neck, Shoulder and Wrist Pain G.Gökşenoğlu	<b>Independent Learning</b>	<b>Independent Learning</b>
10.00- 10.50		<b>Lecture</b> Skeletal Muscle Relaxants E. Genç	<b>Lecture</b> Low Back, Hip and Ankle Pain G.Gökşenoğlu	<b>Pathology Laboratory (Musculoskeletal System)</b> E. Hacıhasanoğlu <b>Group B</b> <b>Group A IL</b>	<b>Independent Learning</b>
11.00- 11.50		<b>Lecture</b> Epidemiology, Prevention and Control of Occupational Diseases and Injuries I H.A. Taşyikan	<b>Lecture</b> Disease Modifying Antirheumatic Drugs E. Nur Özdamar	<b>Lecture</b> Management of Soft Tissue Disorders Ö. Yonga	<b>Lecture</b> Skeletal Dysplasias A. Ç. Kuşkucu
12.00- 12.50		<b>Lecture</b> Epidemiology, Prevention and Control of Occupational Diseases and Injuries II H.A. Taşyikan	<b>Lecture</b> Pharmacology Case Studies E. Nur Özdamar	<b>Lecture</b> Fractures of Children G.Meriç	<b>Lecture</b> Muscular Dystrophies A. Ç.Kuşkucu
12.50 – 14.00		<b>LUNCH BREAK</b>			
14.00- 17.50	<b>Religious Holiday</b>	<b>Lecture</b> Public Health and Physical Activity I H. A.Taşyikan	<b>Lecture</b> Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	<b>Multidisciplinary Case Discussion Panel</b>	<b>Occupational Safety and Health Education</b> N. Sözübir/C.Onay
		<b>Lecture</b> Public Health and Physical Activity II H. A. Taşyikan	<b>Lecture</b> Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	<b>Multidisciplinary Case Discussion Panel</b>	<b>Occupational Safety and Health Education</b> N. Sözübir/C.Onay
		<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
		<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE VI - MUSCULOSKELETAL SYSTEM  
WEEK VI / 16-20 Jun 2025**

	<b>Monday 16-Jun-2025</b>	<b>Tuesday 17- Jun-2025</b>	<b>Wednesday 18- Jun-2025</b>	<b>Thursday 19- Jun-2025</b>	<b>Friday 20- Jun-2025</b>
<b>09.00- 09.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>
<b>10.00- 10.50</b>				<b>COMMITTEE EXAM</b>	
<b>11.00- 11.50</b>					
<b>12.00- 12.50</b>				<b>Program Evaluation Session Committee VI Coordination Committee Members</b>	
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

## **STUDENT COUNSELING**

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for professional life.

The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.

The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

### ***The topics that will be addressed by the consultants are as follows:***

- a. Inform students about the university, faculty and surrounding facilities
- b. Inform students about the courses and help them select courses
- c. Inform students about the education and assessment regulations
- d. Follow students attendance to lectures and success
- e. In case of failure, investigate the causes and cooperate with the students to overcome them
- f. Help students in career planning
- g. Contribute to students adapting the habit of lifelong learning
- h. Guide students to counseling services of the university
- i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
- j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
- k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

### ***The expectations from the student are as follows:***

- a) Contribute to improvement of satisfaction level in the problem areas
- b) Report the social and economic conditions that require consultant's help
- c) Specify expectations from the education and the department from which this training is taken
- d) Give feedback on the counseling services regarding their satisfaction level

Student counsellors will be appointed after finalization of the class list and will be announced to the students.

After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

## CONTACT

---

**Faculty Secretary :**

Tel: +90 216 578 00 00 (3005)

**Dean Secretary:**

Tel: +90 216 578 05 05 – 06

Fax: +90 216 578 05 75

**Student Affairs :**

Tel: +90 216 578 06 86

**Documents Affairs:**

Tel: +90 216 578 05 93

**Coordinator/ Co-coordinators:**

Deniz Kır a , PhD, Prof. (Coordinator), 0216 578 00 00 / [dyat@yeditepe.edu.tr](mailto:dyat@yeditepe.edu.tr)

Yeřim  zarda, MD, Prof. (Co-coordinator), 0216 578 00 00 / [yesim.ozarda@yeditepe.edu.tr](mailto:yesim.ozarda@yeditepe.edu.tr)

Figen Atalay, MD, Prof (Co-coordinator), 0216 578 00 00 / [figen.atalay@yeditepe.edu.tr](mailto:figen.atalay@yeditepe.edu.tr)

Emine Nur  zdamar, MD, Assist. Prof. (Co-coordinator), 0216 578 00 00 / [nur.ozdamar@yeditepe.edu.tr](mailto:nur.ozdamar@yeditepe.edu.tr)

Erdem S ztutar, MD, Assist. Prof (Co-coordinator), 0216 578 00 / [erdem.soztutar@yeditepe.edu.tr](mailto:erdem.soztutar@yeditepe.edu.tr)

Cenk Anda , PhD, Assist. Prof. (Co-coordinator), 0216 578 00 00 / [cenk.andac@yeditepe.edu.tr](mailto:cenk.andac@yeditepe.edu.tr)

Bařak Aru, PhD, Assist. Prof. (Co-coordinator), 0216 578 00 00 / [basak.aru@yeditepe.edu.tr](mailto:basak.aru@yeditepe.edu.tr)

Buřra Nizam, MD, Assist. Prof. (Co-coordinator), 0216 578 00 00 / [busra.nizam@yeditepe.edu.tr](mailto:busra.nizam@yeditepe.edu.tr)

Didem Seven, PhD, Instructor (Co-coordinator), 0216 578 00 00 / [didem.seven@yeditepe.edu.tr](mailto:didem.seven@yeditepe.edu.tr)

G ldal İzbirak, MD, Prof (ICP Coordinator), 0216 578 00 00 / [gizbirak@yeditepe.edu.tr](mailto:gizbirak@yeditepe.edu.tr)

Duygu Altıparmak, MD, Instructor (ICP Co-Coordinator), 0216 578 00 00 / [duygu.altiparmak@yeditepe.edu.tr](mailto:duygu.altiparmak@yeditepe.edu.tr)

Seda G. Yılmaz, PhD. Assoc. Prof. (Elective Courses Coordinator), 0216 578 00 00 / [seda.gulec@yeditepe.edu.tr](mailto:seda.gulec@yeditepe.edu.tr)

Ahmet Sa , MD, Instructor (Elective Courses Co-coordinator) 216 578 00 00 / [ahmet.sac@yeditepe.edu.tr](mailto:ahmet.sac@yeditepe.edu.tr)

**Address:**

Yeditepe University Faculty of Medicine  
İn n  Mah. Kayıřdađı Caddesi,  
26 Ađustos Yerleřimi,  
34755 Atařehir, İstanbul

**Web** : [www.yeditepe.edu.tr](http://www.yeditepe.edu.tr)

<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>

**e-mail:** [tipfakdek@yeditepe.edu.tr](mailto:tipfakdek@yeditepe.edu.tr)

---



YEDİTEPE UNIVERSITY  
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,  
26 Ağustos Yerleşimi,  
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

[www.yeditepe.edu.tr](http://www.yeditepe.edu.tr)  
<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>  
[tipfakdek@yeditepe.edu.tr](mailto:tipfakdek@yeditepe.edu.tr)